Review

Exercise Training in Patients with Chronic Respiratory Diseases: Are Cardiovascular Comorbidities and Outcomes Taken into Account?—A Systematic Review

Ana Machado, Kirsten Quadflieg, Ana Oliveira, Charly Keytsman, Alda Marques, Dominique Hansen and Chris Burtin

1 REVAL—Rehabilitation Research Center, Faculty of Rehabilitation Sciences, Hasselt University, 3590 Diepenbeek, Belgium
2 Respiratory Research and Rehabilitation Laboratory (Lab3R), School of Health Sciences (ESSUA), University of Aveiro, 3810 Aveiro, Portugal
3 Respiratory Medicine, West Park Healthcare Centre, Toronto, ON M6M 2J5, Canada
4 School of Rehabilitation Sciences, Faculty of Health Sciences, McMaster University, Hamilton, ON L8S 4K1, Canada
5 BIOMED—Biomedical Research Institute, Hasselt University, 3590 Diepenbeek, Belgium
6 Institute of Biomedicine (iBiMED), University of Aveiro, 3810 Aveiro, Portugal
7 Jessa hospital, Heart Centre Hasselt, 3500 Hasselt, Belgium

* Correspondence: chris.burtin@uhasselt.be

Received: 15 July 2019; Accepted: 10 September 2019; Published: 13 September 2019

Abstract: Patients with chronic obstructive pulmonary disease (COPD), asthma and interstitial lung diseases (ILD) frequently suffer from cardiovascular comorbidities (CVC). Exercise training is a cornerstone intervention for the management of these conditions, however recommendations on tailoring programmes to patients suffering from respiratory diseases and CVC are scarce. This systematic review aimed to identify the eligibility criteria used to select patients with COPD, asthma or ILD and CVC to exercise programmes; assess the impact of exercise on cardiovascular outcomes; and identify how exercise programmes were tailored to CVC. PubMed, Scopus, Web of Science and Cochrane were searched. Three reviewers extracted the data and two reviewers independently assessed the quality of studies with the Quality Assessment Tool for Quantitative Studies. MetaXL 5.3 was used to calculate the individual and pooled effect sizes (ES). Most studies (58.9%) excluded patients with both stable and unstable CVC. In total, 26/42 studies reported cardiovascular outcomes. Resting heart rate was the most reported outcome measure (n = 13) and a small statistically significant effect (ES = −0.23) of exercise training on resting heart rate of patients with COPD was found. No specific adjustments to exercise prescription were described. Few studies have included patients with CVC. There was a lack of tailoring of exercise programmes and limited effects were found. Future studies should explore the effect of tailored exercise programmes on relevant outcome measures in respiratory patients with CVC.

Keywords: exercise; chronic lung disease; chronic obstructive pulmonary disease; COPD; asthma; interstitial lung disease; ILD; cardiovascular comorbidities; cardiovascular outcomes

1. Background

Chronic obstructive pulmonary disease (COPD), asthma and interstitial lung diseases (ILD) are among the most representative chronic respiratory diseases in the world [1,2]. These diseases affect over 1 billion people and have a significant impact on patients’ disability and quality of life (9.5% of...
the disability-adjusted life years in 2010 [3]), being a leading contributor to disease burden and one of the top causes of death worldwide (over 3 million deaths in 2016) [2–4].

In recent years, the association between chronic respiratory diseases and cardiovascular diseases has attracted huge interest in clinical research [5]. Cardiovascular diseases (e.g., arterial hypertension, coronary artery disease, congestive heart failure, peripheral vascular disease and pulmonary hypertension) are among the most prevalent and impactful comorbidities in patients with COPD (13%–68% of population), asthma (3%–25% of population) and ILD (8%–86% of population) [6–13]. Namely, they are responsible for further impairing patients’ functional status and health-related quality of life, increasing the risk of hospitalization and mortality (hazard ratio 1.1–3.4 [14–17]), and contributing to a higher economic and societal burden, and worse prognosis [7,9,10,12]. The need to look beyond the lungs while treating these patients is, therefore, evident [18]. In this regard, a comprehensive assessment and management of these cardiovascular comorbidities with tailored interventions has been recommended [7,12,19,20].

Exercise training is a cornerstone intervention in both pulmonary and cardiac rehabilitation [21,22]. It relieves symptoms and improves functionality, exercise tolerance and health-related quality of life in patients with chronic respiratory and cardiovascular diseases [21,22], and therefore might be a promising intervention for the management of patients with these co-occurring conditions. Nevertheless, studies have shown that these effects are usually reduced in patients suffering from chronic respiratory diseases with accompanying cardiovascular comorbidities compared to those without cardiovascular comorbidities [7,19,23]. Moreover, recommendations on how to adjust exercise programmes to co-existing cardiovascular conditions in COPD, asthma and ILD are scarce.

Therefore, in order to inform evidence-based statements, this systematic review aimed to: (i) identify the eligibility criteria in terms of cardiovascular disease that have been used to refer patients with COPD, asthma and ILD for studies investigating the effectiveness of exercise programmes of at least 3 months; (ii) assess the impact of at least 3 months of exercise training on cardiovascular outcomes in these patients; and (iii) identify how the exercise programmes have been tailored to patients’ cardiovascular comorbidities.

2. Methods

2.1. Search Strategy

This systematic review was reported according to the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines [24] and was conducted in two phases. Phase 1 identified the eligibility criteria that have been used to select patients with cardiovascular comorbidities in clinical trials investigating the effectiveness of exercise programmes of at least 3 months; (ii) assess the impact of at least 3 months of exercise training on cardiovascular outcomes in these patients; and (iii) identify how the exercise programmes have been tailored to patients’ cardiovascular comorbidities.

A systematic literature search was performed in May 2019 on the following electronic databases: PubMed, Scopus, Web of Science and Cochrane. The search terms were limited to titles, abstracts and keywords/MeSH terms. The full search strategy is presented in Appendix A.

2.2. Eligibility Criteria and Study Selection

For phase 1, studies were included if they (i) studied adult patients with stable COPD, asthma and/or ILD (i.e., 4 weeks without exacerbations); (ii) implemented at least 12 weeks of exercise training (i.e., endurance and/or strength training) as an intervention [25]; (iii) implemented at least 2 directly supervised exercise sessions per week [26]; (iv) were original prospective quantitative studies; and (v) were written in Portuguese, English, French, Dutch or Spanish languages. Retrospective studies, case studies, case series, abstracts and studies involving alternative modalities of exercise (e.g., yoga, tai chi, qigong) were excluded. After removing duplicates, three reviewers (AM, KQ and AO) assessed all the potential studies identified. Studies were selected based on their titles and abstracts. When the title
and abstract were potentially relevant to the purpose of the review, the full text was read carefully to decide on its inclusion. A fourth reviewer (CB) was consulted to solve any disagreements.

For phase 2, studies included in phase 1 that specified the prevalence of cardiovascular comorbidities (i.e., any cardiovascular condition co-existing with the respiratory disease, identified by doing an objective patients’ assessment, checking their medical records or ask patients to self-report their comorbidities) in the baseline characteristics of the population under study and/or reported at least one cardiovascular outcome (i.e., heart rate, systolic and diastolic blood pressure, flow-mediated dilation, pulse-wave velocity, intima thickness of artery carotid, cardiac function and structure, heart rate variability, ECG analysis and blood lipid profile) were included.

2.3. Quality Assessment and Data Extraction

Two reviewers (KQ and AO) independently assessed the quality of the studies included in phase 2 with the Quality Assessment Tool for Quantitative Studies, developed by the Effective Public Health Practice Project, Canada [27]. This tool assesses six domains of methodological quality: (i) selection bias; (ii) study design; (iii) confounders; (iv) blinding; (v) data collection methods; and (vi) withdrawals and dropouts [27]. Each domain is rated as “strong”, “moderate” or “weak”, according to a standardized guide, and the overall rating of the study is determined based on the total number of “strong” and “weak” scores [27].

In phase 1, data regarding the eligibility criteria (i.e., inclusion and exclusion criteria) used to select patients for the study were extracted from all included studies. Afterwards, all conditions that would preclude patients’ participation in the exercise programmes, reported either as reasons for inclusion (e.g., absence of severe cardiovascular disease) or exclusion (e.g., presence of severe cardiovascular disease) of these patients, were compiled and reported as exclusion criteria. Additionally, data from the studies included in phase 2 were extracted in a predesigned structured table format comprising the following topics: study (first author, year of publication, country); study design; population (number of participants, diagnosis, age, gender, forced expiratory volume in 1 s (FEV₁), forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO)); intervention (type and intensity of intervention); duration and frequency (duration of the intervention, duration and frequency of sessions); outcome and outcome measure; and results. For the scope of this review, only cardiovascular outcomes and outcome measures were considered.

2.4. Data Analysis and Synthesis

Inter-rater agreement analysis using Cohen’s kappa was used to explore the consistency of the quality assessment performed by the two reviewers. The value of Cohen’s kappa ranges from 0 to 1 and can be interpreted as slight (≤0.2), fair (0.21–0.4), moderate (0.41–0.6), substantial (0.61–0.8), or almost perfect (≥0.81) agreement [28]. The statistical analysis was performed using IBM SPSS 24.0 (IBM, Armonk, New York, NY, USA).

Whenever possible, effect sizes (ES) were calculated and a meta-analysis was performed. ES were calculated as Cohens’ d based on the Pre/Post means and standard deviations or mean differences and standard deviations, according to the formula of Morris [29], and interpreted as small (≥0.2), medium (≥0.5) or large (≥0.8) [30]. Meta-analysis was performed on MetaXL 5.3. Pooled effect estimates were calculated with the inverse variance technique assuming a fixed-effects model. The input data were the Cohen’s d value of each study and the respective standard error. The output was the pooled Cohen’s d value and corresponding confidence intervals. Homogeneity among the studies was evaluated using Cochran’s Q test and the $I^2$ statistic.
3. Results

3.1. Study Selection

The literature search provided a total of 50,970 records. After duplicates removal, 29,756 records were screened for relevant content through title and abstract and 29,248 were excluded. The full text of 508 potentially relevant articles was assessed. From these, 180 articles were included in phase 1 and 42 in phase 2 (Figure 1).

![Figure 1. PRISMA flowchart of the included studies.](image)

3.2. Phase 1: Criteria Used to Exclude Patients with Cardiovascular Comorbidities from Exercise Programmes

The 180 studies included were conducted between 1987 and 2019. In total, 156 studies included patients with COPD [23,31–185], 15 studies included patients with asthma [46,52,63,78,185–195] and 16 studies included patients with ILD [87,185,196–209].

Forty-four different exclusion criteria were found in studies with patients with COPD (Figure 2). From these, exercise-limiting conditions [34,36,40,53,60,61,89,92,104,114,125,134,135,138,148,157,166–170,173,174,179,181,183,184] (n = 27; 17.3%) was the most reported exclusion criterion, followed by general cardiovascular disease [32,39,44,70,74,75,94,100,103,107,109,112,130,152,153,160,164,171]
(n = 18; 11.5%) and unstable cardiovascular disease \([38,47,53,65,66,98,99,101,108,116–119,133,137,146,147,180]\) (n = 18; 11.5%). Thirty-four (21.8%) of the studies \([23,48,50,55,63,67,69,73,77–80,83,84,86,88,91,95,97,110,111,115,122,126,127,132,142,149,150,155,161,165,175,185]\) did not report any information regarding the eligibility criteria for cardiovascular comorbidities.

**Figure 2.** Exclusion criteria reported in studies with patients with chronic obstructive pulmonary disease (COPD) (n = 156 studies).

In studies including patients with asthma, 10 different exclusion criteria were found (Figure 3). General cardiovascular disease \([186,191,192]\) (n = 3; 20.0%) was the most reported criterion, followed by contraindications to exercise training and/or testing \([194,195]\) (n = 2; 13.3%). Seven (46.7%) studies \([63,78,185,187,189,190,193]\) did not report information about exclusion criteria.

Studies in patients with ILD reported 10 different exclusion criteria (Figure 4). From these, unstable cardiovascular disease \([198,199,202,203,208,209]\) (n = 6; 37.5%) was the most reported criterion, followed by contraindications to exercise training and/or testing (e.g., unstable angina, recent myocardial infarction or cerebrovascular accident) \([201,204,207]\) (n = 3; 18.8%). Four (25.0%) studies \([185,197,205,206]\) did not report any information about exclusion criteria.

In general, 22.8% of the studies \([23,48,50,55,63,67,69,73,77–80,83,84,86,88,91,95,97,110,111,115,122,126,127,132,142,149,150,155,161,165,175,185,187,189,190,193,197,205,206]\) did not report information about the eligibility criteria, 18.3% of the studies \([33,42,54,65,66,72,82,96,98,99,101,108,116–119,128,137,141,143,145,146,180,182,194,195,200–203,207–209]\) only excluded patients with acute or unstable cardiovascular comorbidities that contraindicated exercise training, and 58.9% of the studies \([31,32,34–41,43–47,49,51–53,56–62,64,68,70,71,74–76,81,85,87,89,90,92–94,100,102–107,109,112–114,120,121,123–125,129–131,133–136,138–140,144,147,148,151–154,156–160,162–164,166–174,176–179,181,183,184,186,188,191,192,196,198,199,204]\) excluded both stable and unstable cardiovascular comorbidities.
Figure 3. Exclusion criteria reported in studies with patients with asthma ($n = 15$ studies).

Figure 4. Exclusion criteria reported in studies with patients with interstitial lung diseases (ILD) ($n = 16$ studies).
3.3. Phase 2: Impact of Exercise Training on Cardiovascular Outcomes and Design of the Exercise Programmes

3.3.1. Quality Assessment

Results of the methodological quality assessment are presented in Table 1. Most of the studies \((n = 24; 57.1\%)\) were of weak quality. The agreement between the two reviewers was substantial \((k = 0.72; 95\%CI = 0.53–0.91; p < 0.001; \text{percentage of agreement} = 85.7\%)\).

3.3.2. Study Characteristics

Characteristics of the included studies are shown in Tables 2–4. From the 42 included studies, 32 studies included patients with COPD \([33,37,42–44,48,49,53–55,57,59,68,80,85,90,101,104,106–108, 120,121,123,124,128,129,136,146,147,151,167]\), two studies included patients with asthma \([186,189]\) and eight studies included patients with ILD \([196,198,203,207–209]\). Most studies were randomized controlled trials \((n = 24; 57.1\%)\) \([37,43,44,49,53,80,85,120,121,123,124,129,146,147,151,167,186,189,196, 198,202,207–209]\).

In total, 1704 patients \((65.2\% \text{ male}; \text{data gathered from 34 studies})\) with a weighted mean age of 65.4 years old and a mean FEV\(_1\) of 53.7\% of predicted \((\text{data gathered from 36 studies})\) were enrolled in the included studies.

Only 13 studies in patients with COPD \([33,42–44,48,54,55,59,68,85,101,151,167]\) and six studies in patients with ILD \([196,198,203,207–209]\) specified the presence of patients with cardiovascular comorbidities on the population’s baseline characteristics. No studies reporting to include patients with cardiovascular comorbidities were found in asthma. Studies in patients with COPD included patients suffering from arterial hypertension \([33,42–44,48,54,68,85,151]\) \((\text{nine studies}; 314 \text{ patients})\), cardiovascular diseases \([43,44,48,55,85,101,151,167]\) \((\text{nine studies}; 247 \text{ patients})\), circulatory problems \([42–44,85]\) \((\text{four studies}; 84 \text{ patients})\), coronary heart disease \([42]\) \((\text{one study}; 54 \text{ patients})\), congestive heart failure \([33,54]\) \((\text{two studies}; 10 \text{ patients})\), dyslipidaemia \([33,54]\) \((\text{two studies}; 11 \text{ patients})\) and ischemic cardiomyopathy \([33]\) \((\text{one study}; 18 \text{ patients})\). Studies in patients with ILD included patients suffering from arterial hypertension \([196,203,207–209]\) \((\text{five studies}; 49 \text{ patients})\), coronary heart disease \([207–209]\) \((\text{three studies}; 21 \text{ patients})\), congestive heart failure \([203]\) \((\text{one study}; 10 \text{ patients})\), pulmonary hypertension \([207–209]\) \((\text{three studies}; 28 \text{ patients})\) and history of heart disease \([198]\) \((\text{one study}; 1 \text{ patient})\). From these, only three studies \([196,207,209]\) conducted in patients with ILD reported cardiovascular outcomes and outcome measures.

Nineteen studies in patients with COPD \([37,49,53,57,80,90,104,106–108,120,121,123,124,128,129, 136,146,147]\), two studies in asthma \([186,189]\) and five studies in ILD \([196,201,202,207,209]\) reported cardiovascular outcomes and outcome measures. Studies conducted in patients with COPD presented a large variety of outcome measures, while studies conducted in patients with asthma were mainly focused on blood lipid profile \([187,190]\) \((n = 2)\) and studies in patients with ILD reported mainly resting heart rate \([196,201,209]\) \((n = 3)\) and blood pressure \([196,207,209]\) \((n = 3)\). The most reported outcome measure was resting heart rate \([37,57,90,106,107,121,123,124,129,136,196,201,209]\) \((n = 13; \text{ES} = −0.63; 0.11)\).
Table 1. Quality assessment of the studies included in phase 2 ($n = 42$) with the Quality Assessment Tool for Quantitative Studies.

| Study                        | Selection Bias | Study Design | Confounders | Blinding | Data Collection Method | Withdrawals and Drop-Outs | Global Rating |
|------------------------------|----------------|--------------|-------------|----------|------------------------|----------------------------|---------------|
| Cochrane et al., 1990        | 3              | 1            | 1           | 3        | 1                      | 3                          | 3             |
| Berry et al., 1999           | 2              | 2            | 3           | 3        | 1                      | 1                          | 3             |
| Foy et al., 2001             | 3              | 1            | 3           | 3        | 1                      | 1                          | 3             |
| Berry et al., 2003           | 2              | 1            | 1           | 2        | 1                      | 1                          | 1             |
| Panton et al., 2004          | 2              | 1            | 3           | 3        | 1                      | 1                          | 3             |
| Marquis et al., 2008         | 2              | 1            | 3           | 1        | 1                      | 3                          | 3             |
| Averna et al., 2009          | 3              | 1            | 1           | 3        | 1                      | 1                          | 2             |
| Berry et al., 2010           | 3              | 1            | 1           | 2        | 1                      | 1                          | 2             |
| Rejbi et al., 2010           | 2              | 1            | 2           | 3        | 1                      | 1                          | 2             |
| Camillo et al., 2011         | 2              | 1            | 1           | 3        | 1                      | 1                          | 2             |
| Lan et al., 2011             | 3              | 2            | 2           | 3        | 1                      | 3                          | 3             |
| Corhay et al., 2012          | 3              | 2            | 3           | 2        | 1                      | 2                          | 3             |
| Georgiopoulou et al., 2012   | 2              | 2            | NA          | 3        | 1                      | 1                          | 2             |
| Lan et al., 2013             | 2              | 2            | NA          | 3        | 1                      | 3                          | 3             |
| Cheng et al., 2014           | 3              | 2            | NA          | 3        | 1                      | 3                          | 3             |
| Gaunaurd et al., 2014        | 3              | 1            | 1           | 3        | 1                      | 1                          | 3             |
| Vainshelboim et al., 2014    | 3              | 1            | 1           | 3        | 1                      | 1                          | 3             |
| Borghi-Silva et al., 2015    | 2              | 1            | 1           | 2        | 1                      | 1                          | 1             |
| Campos et al., 2015          | 2              | 2            | NA          | 3        | 1                      | 1                          | 2             |
| Leite et al., 2015           | 2              | 1            | 1           | 3        | 1                      | 3                          | 3             |
| Marcellis et al., 2015       | 2              | 2            | NA          | 3        | 1                      | 2                          | 2             |
| Mkacher et al., 2015         | 2              | 1            | 1           | 3        | 1                      | 1                          | 2             |
| Spielmanns et al., 2015      | 3              | 1            | 1           | 2        | 1                      | 3                          | 3             |
| Vainshelboim et al., 2015    | 2              | 1            | 1           | 3        | 1                      | 1                          | 2             |
| Boström et al., 2016         | 3              | 1            | 1           | 2        | 1                      | 1                          | 2             |
| Cardoso et al., 2016         | 2              | 1            | 3           | 3        | 1                      | 1                          | 3             |
| El-Kader et al., 2016        | 3              | 1            | 1           | 3        | 1                      | 1                          | 3             |
| Engel et al., 2016           | 3              | 1            | 1           | 1        | 1                      | 1                          | 1             |
| Boeselt et al., 2017         | 3              | 1            | 1           | 3        | 1                      | 2                          | 3             |
| Kanao et al., 2017           | 3              | 2            | NA          | 3        | 1                      | 1                          | 3             |
| Pacheco et al., 2017         | 2              | 3            | NA          | 3        | 1                      | 1                          | 3             |
| Papp et al., 2017            | 3              | 1            | 3           | 3        | 1                      | 2                          | 3             |
### Table 1. Cont.

| Study                  | Selection Bias | Study Design | Confounders | Blinding | Data Collection Method | Withdrawals and Drop-Outs | Global Rating |
|------------------------|----------------|--------------|-------------|----------|------------------------|----------------------------|---------------|
| Vainshelboim et al., 2017 | 2              | 1            | 1           | 3        | 1                      | 1                          | 2             |
| Vasilopoulou et al., 2017 | 3              | 1            | 3           | 3        | 1                      | 1                          | 3             |
| Lan et al., 2018       | 3              | 2            | NA          | 3        | 1                      | 1                          | 3             |
| Moezy et al., 2018     | 3              | 1            | 1           | 3        | 1                      | 1                          | 3             |
| Naz et al., 2018a      | 2              | 2            | NA          | 3        | 1                      | 1                          | 2             |
| Naz et al., 2018b      | 3              | 1            | 1           | 3        | 1                      | 1                          | 3             |
| Silva et al., 2018     | 2              | 1            | 1           | 3        | 1                      | 1                          | 2             |
| Charikiopoulou et al., 2019 | 2              | 2            | 3           | 3        | 1                      | 1                          | 3             |
| Mekki et al., 2019     | 2              | 1            | 1           | 2        | 1                      | 2                          | 2             |
| Silva et al., 2019     | 2              | 1            | 1           | 3        | 1                      | 1                          | 2             |

Legend: 1 = strong quality; 2 = moderate quality; 3 = weak quality; NA, not applicable.
Table 2. Characteristics of the studies in patients with COPD included in phase 2 (i.e., studies that specified the prevalence of cardiovascular comorbidities in the baseline characteristics of the population under study and/or reported at least one cardiovascular outcome) (*n* = 32).

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|-----------------------------------|
| Berry et al., 1999 | Non-controlled study | 151 patients with COPD | All groups: Aerobic and strength training | All groups: | All groups: | All groups: |
| United States of America | | Mild disease group: 99 (54♂; 67.4 ± 6.1 years; FEV₁ 68.0 ± 1.2%pred) | Dyspnoea 3–4 in the mBorg | 12 weeks | 12 weeks | 12 weeks |
| | | Arterial hypertension: *n* = 44 | | 3 sessions/week | 3 sessions/week | 1 h/session |
| | | Circulatory problems: *n* = 14 | | | | |
| | | Coronary heart disease: *n* = 34 | | | | |
| | | Moderate disease group: 36 (22♂; 68.3 ± 6.2 years; FEV₁ 41.9 ± 0.7%pred) | | | | |
| | | Arterial hypertension: *n* = 16 | | | | |
| | | Circulatory problems: *n* = 5 | | | | |
| | | Coronary heart disease: *n* = 12 | | | | |
| | | Severe disease group: 16 (10♂; 66.1 ± 5.6 years; FEV₁ 30.1 ± 0.9%pred) | | | | |
| | | Arterial hypertension: *n* = 7 | | | | |
| | | Circulatory problems: *n* = 2 | | | | |
| | | Coronary heart disease: *n* = 8 | | | | |
| Foy et al., 2001 | Randomized controlled trial | 140 patients with COPD | All groups: Aerobic and strength training | 3 sessions/week | 3 sessions/week | 3 sessions/week |
| United States of America | | Short-term intervention group: 70 (39♂; 66.9 ± 5.9 years; FEV₁ 59.1 ± 17.2%pred) | Dyspnoea 3–4 in the mBorg | 12 weeks | 12 weeks |
| | | Arterial hypertension: *n* = 29 | | 55–65 min/session | |
| | | Circulatory problems: *n* = 14 | | | |
| | | Cardiovascular disease: *n* = 27 | | | |
| | | Long-term intervention group: 70 (39♂; 68.4 ± 6.0 years; FEV₁ 57.6 ± 18.4%pred) | | | |
| | | Arterial hypertension: *n* = 32 | | | |
| | | Circulatory problems: *n* = 9 | | | |
| | | Cardiovascular disease: *n* = 24 | | | |
### Table 2. Cont.

| Study and Country          | Study Design          | Population                                                                 | Intervention                                                                 | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|----------------------------|-----------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------|---------------------------------------------|-----------------------------------|
| Berry et al., 2003         | United States of America | 140 patients with COPD                                                        | Short-term intervention group: 70 (39♂; 66.9, 95%CI (65.5; 68.3) years; FEV₁ 59.1, 95%CI (55.0; 63.2)%pred) | 3 sessions/week 1 h/session | Short-term intervention group 1: 3 months   | Aerobic training group: Pre 177.0 ± 29.0 vs. Post 186.0 ± 30.0, p > 0.05 ES = 0.31 |
|                            | Randomized controlled trial | Arterial hypertension: n = 29                                               | Circulatory problems: n = 14                                                  |                        |                                             | Aerobic+strength training group: Pre 195.0 ± 35.0 vs. Post 199.0 ± 35.0, p > 0.05 ES = 0.11 |
|                            |                       | Long-term intervention group: 70 (39♂; 68.4, 95%CI (67.0; 69.8) years; FEV₁ 57.6, 95%CI (53.2; 62.0)%pred) | Cardiovascular disease: n = 27                                               |                        |                                             |                                  |
|                            |                       | Arterial hypertension: n = 32                                               | Circulatory problems: n = 9                                                   |                        |                                             |                                  |
|                            |                       | Cardiovascular disease: n = 24                                              |                                                                                |                        |                                             |                                  |
| Panton et al., 2004        | United States of America | 17 patients with COPD                                                        | Aerobic training group: 8 (2♂; 63.0 ± 8.0 years; FEV₁ 39.5 ± 31.9%pred)     | 12 weeks               | Aerobic + strength training group: Pre 201.0 ± 34.0 vs. Post 193.0 ± 23.0, p > 0.05 ES = −0.28 |
|                            | Non-randomized controlled trial | Aerobic training group: 9 (6♂; 61.0 ± 7.0 years; FEV₁ 41.9 ± 16.0%pred)   | Aerobic+strength training group: 2 sessions/week 60 min/session              |                        |                                             | Aerobic training group: Pre 217.0 ± 46.0 vs. Post 217.0 ± 46.0, p > 0.05 ES = 0.00 |
|                            |                       | Aerobic+strength training group: 50%–70% of HR reserve                     | Aerobic + strength training group: 4 sessions/week (2 of each training) 45–60 min/session |
|                            |                       |                                                                                |                                                                                |                        |                                             |                                  |
|                            |                       | Cholesterol – HDL (mg/dl)                                                   |                                                                                |                        |                                             |                                  |
|                            |                       | Aerobic training group: 62.0 ± 21.0 vs. 62.0 ± 20.0, p > 0.05 ES = 0.00    |                                                                                |                        |                                             |                                  |
|                            |                       | Aerobic+strength training group: Pre 55.0 ± 16.0 vs. Post 53.0 ± 12.0, p > 0.05 ES = −0.14 |                                                                                |                        |                                             |                                  |
Table 2. Cont.

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|----------------------------------|
|                   |              |            |              |                        | Aerobic training group: Pre                   |                                 |
|                   |              |            |              |                        | 129.0 ± 34.0 vs. Post 132.0 ± 35.0, p > 0.05 | E5 = 0.09                         |
|                   |              |            |              |                        | Aerobic+strength training group: Pre 122.0 ± 21.0 vs. Post 118.0 ± 15.0, p > 0.05 | E5 = −0.22                     |
| Marquis et al., 2008 | Randomized controlled trial | 16 patients with COPD | All groups: Aerobic training 80% of WRmax | All groups: 12 weeks 3 sessions/week 30 min/session |                                |                                 |
| Canada            |              | 10 (7♂; 67.0 ± 7.0 years; FEV1 50.0 ± 19.0%pred; FVC 63.0 ± 16.0%pred; DLCO 80.0 ± 19.0%pred) |                          |                                      |                                |                                 |
|                   |              | 6 (1♂; 72.0 ± 5.0 years; FEV1 39.0 ± 9.0%pred; FVC 63.0 ± 15.0%pred; DLCO 63.0 ± 18.0%pred) |                          |                                      |                                |                                 |
|                   |              | Irbesartan+exercise group: |                          |                                      |                                |                                 |
|                   |              | 10 (7♂; 67.0 ± 7.0 years; FEV1 50.0 ± 19.0%pred; FVC 63.0 ± 16.0%pred; DLCO 80.0 ± 19.0%pred) |                          |                                      |                                |                                 |
|                   |              | Placebo+exercise group: |                          |                                      |                                |                                 |
|                   |              | 6 (1♂; 72.0 ± 5.0 years; FEV1 39.0 ± 9.0%pred; FVC 63.0 ± 15.0%pred; DLCO 63.0 ± 18.0%pred) |                          |                                      |                                |                                 |

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|----------------------------------|
|                   |              |            |              |                        | Cholesterol – LDL (mg/dl)                   |                                 |
|                   |              |            |              |                        | Aerobic training group: Pre 129.0 ± 34.0 vs. Post 132.0 ± 35.0, p > 0.05 | E5 = 0.09                         |
|                   |              |            |              |                        | Aerobic+strength training group: Pre 122.0 ± 21.0 vs. Post 118.0 ± 15.0, p > 0.05 | E5 = −0.22                     |
|                   |              |            |              |                        | Cholesterol – Triglycerides (mg/dl)         |                                 |
|                   |              |            |              |                        | Aerobic training group: Pre 151.0 ± 65.0 vs. Post 185.0 ± 87.0, p < 0.05 | E5 = 0.44                         |
|                   |              |            |              |                        | Aerobic+strength training group: Pre 141.0 ± 132.0 vs. Post 135.0 ± 73.0, p > 0.05 | E5 = −0.06                     |
|                   |              |            |              |                        | Total cholesterol/HDL ratio                |                                 |
|                   |              |            |              |                        | Aerobic training group: Pre 3.8 ± 1.1 vs. Post 3.9 ± 1.1, p > 0.05 | E5 = 0.09                         |
|                   |              |            |              |                        | Aerobic+strength training group: Pre 3.8 ± 0.8 vs. Post 3.8 ± 0.8, p > 0.05 | E5 = 0.00                         |
|                   |              |            |              |                        | Systolic blood pressure at rest (mmHg)     |                                 |
|                   |              |            |              |                        | Irbesartan+exercise group: Pre 151.0 ± 19.0 vs. Post 131.0 ± 18.0, p < 0.05 | E5 = −1.08                         |
|                   |              |            |              |                        | Placebo+exercise group: Pre 140.0 ± 15.0 vs. Post 136.0 ± 15.0, p > 0.05 | E5 = −0.27                         |
|                   |              |            |              |                        | Mean systolic blood pressure during 24 h (mmHg) |                                 |
|                   |              |            |              |                        | Irbesartan+exercise group: Pre 135.0 ± 9.0 vs. Post 126.0 ± 12.0, p < 0.01 | E5 = −0.85                         |
|                   |              |            |              |                        | Placebo+exercise group: Pre 130.0 ± 14.0 vs. Post 128.0 ± 8.0, p > 0.05 | E5 = −0.18                         |
Table 2. Cont.

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|----------------------------------|
|                   |              |            |              |                        | Mean systolic blood pressure at daytime (mmHg) | Irbesartan+exercise group: Pre 139.0 ± 11.0 vs. Post 129.0 ± 15.0, p < 0.01 ES = −0.76 Placebo+exercise group: Pre 130.0 ± 14.0 vs. Post 131.0 ± 8.0, p > 0.05 ES = 0.09 |
|                   |              |            |              |                        | Mean systolic blood pressure at nighttime (mmHg) | Irbesartan+exercise group: Pre 125.0 ± 8.0 vs. Post 121.0 ± 10.0, p > 0.05 ES = −0.44 Placebo+exercise group: Pre 128.0 ± 16.0 vs. Post 121.0 ± 9.0, p > 0.05 ES = −0.54 |
|                   |              |            |              |                        | Diastolic blood pressure at rest (mmHg) | Irbesartan+exercise group: Pre 78.0 ± 8.0 vs. Post 71.0 ± 10.0, p < 0.05 ES = −0.77 Placebo+exercise group: Pre 72.0 ± 8.0 vs. Post 68.0 ± 10.0, p > 0.05 ES = −0.44 |
|                   |              |            |              |                        | Mean diastolic blood pressure during 24 h (mmHg) | Irbesartan+exercise group: Pre 76.0 ± 9.0 vs. Post 72.0 ± 8.0, p < 0.05 ES = −0.47 Placebo+exercise group: Pre 70.0 ± 3.0 vs. Post 70.0 ± 8.0, p > 0.05 ES = 0.00 |
|                   |              |            |              |                        | Mean diastolic blood pressure at daytime (mmHg) | Irbesartan+exercise group: Pre 80.0 ± 11.0 vs. Post 74.0 ± 10.0, p < 0.05 ES = −0.84 Placebo+exercise group: Pre 71.0 ± 2.0 vs. Post 72.0 ± 7.0, p > 0.05 ES = 0.19 |
Table 2. Cont.

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|-----------------------------------|
|                   |              |            |              |                        | Mean diastolic blood pressure at nighttime (mmHg) | Irbesartan-exercise group: Pre 68.0 ± 6.0 vs. Post 67.0 ± 7.0, p > 0.05, ES = −0.15 |
|                   |              |            |              |                        |                                             | Placebo-exercise group: Pre 66.0 ± 6.0 vs. Post 65.0 ± 8.0, p > 0.05, ES = −0.14 |
|                   |              |            |              |                        | Standard deviation of all NN intervals (ms) | Irbesartan-exercise group: Pre 102.0 ± 28.0 vs. Post 144.0 ± 36.0, p > 0.05, ES = 1.30 |
|                   |              |            |              |                        |                                             | Placebo-exercise group: Pre 121.0 ± 27.0 vs. Post 113.0 ± 38.0, p > 0.05, ES = −0.24 |
|                   |              |            |              |                        | Adjacent normal-to-normal (NN) intervals differing by more than 50 ms (%) | Irbesartan-exercise group: Pre 9.0 ± 9.0 vs. Post 9.0 ± 8.0, p > 0.05, ES = 0.00 |
|                   |              |            |              |                        |                                             | Placebo-exercise group: Pre 10.0 ± 9.0 vs. Post 10.0 ± 8.0, p > 0.05, ES = 0.00 |
|                   |              |            |              |                        | Square root of the mean squared differences of successive NN intervals (ms) | Irbesartan-exercise group: Pre 30.0 ± 12.0 vs. Post 29.0 ± 11.0, p > 0.05, ES = −0.09 |
|                   |              |            |              |                        |                                             | Placebo-exercise group: Pre 31.0 ± 11.0 vs. Post 30.0 ± 10.0, p > 0.05, ES = −0.10 |
|                   |              |            |              |                        | Very low frequency (ms) | Irbesartan-exercise group: Pre 3.3 ± 0.2 vs. Post 3.3 ± 0.2, p > 0.05, ES = 0.00 |
|                   |              |            |              |                        |                                             | Placebo-exercise group: Pre 3.1 ± 0.2 vs. Post 3.1 ± 0.5, p > 0.05, ES = 0.07 |
| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|-----------------------------------|
| **Averna et al., 2009**<br>Italy | Randomized controlled trial | 56 patients with COPD (29♂; 69.0 ± 5.0 years; FEV1 82.0 ± 16.6%pred; FVC 91.0 ± 17.4%pred) | Aerobic and strength training 40%–50% of HR reserve 50% of 1 RM | 12 weeks 3 sessions/week 60 min/session | Irbesartan-exercise group: Pre 2.9 ± 0.3 vs. Post 2.9 ± 0.3, p > 0.05 ES = −0.03 | Low frequency (ms) |
| | | | | | Placebo-exercise group: Pre 2.8 ± 0.4 vs. Post 2.8 ± 0.4, p > 0.05 ES = 0.02 | |
| | | | | | Irbesartan-exercise group: Pre 2.4 ± 0.3 vs. Post 2.4 ± 0.4, p > 0.05 ES = −0.03 | High frequency (ms) |
| | | | | | Placebo-exercise group: Pre 2.4 ± 0.4 vs. Post 2.4 ± 0.5, p > 0.05 ES = −0.12 | |
| | | | | | Irbesartan-exercise group: Pre 3.0 ± 1.3 vs. Post 3.1 ± 1.3, p > 0.05 ES = 0.08 | Low frequency/High frequency ratio |
| | | | | | Placebo-exercise group: Pre 2.1 ± 1.0 vs. Post 2.4 ± 1.0, p > 0.05 ES = −0.27 | |
| **Berry et al., 2010**<br>United States of America | Randomized controlled trial | 89 patients with COPD (48♂; 66.0 ± 10.0 years; FEV1 53.0 ± 18.5%pred) Arterial hypertension: n = 47 Circulatory problems: n = 17 Cardiovascular disease: n = 39 | Aerobic and strength training Dyspnoea 3–5 in the mBorg | 12 weeks 3 sessions/week 1 h/session | Irbesartan-exercise group: Pre 65.0 ± 10.0 vs. Post 65.0 ± 9.0, p = 0.64 ES = 0.00 | HR at rest (bpm) |
| | | | | | Placebo-exercise group: Pre 137.0 ± 12.0 vs. Post 131.0 ± 12.0, p = 0.001 ES = −0.70 | Systolic blood pressure at rest (mmHg) |
| | | | | | Pre 84.0 ± 6.0 vs. Post 80.0 ± 7.0, p = 0.001 ES = −0.61 | Diastolic blood pressure at rest (mmHg) |
### Table 2. Cont.

| Study and Country       | Study Design            | Population                                                                 | Intervention                                                                 | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------------|-------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------|---------------------------------------------|------------------------------------|
| Rejbi et al., 2010      | Non-randomized controlled trial | 26 patients with COPD (61.0 ± 4.0 years; FEV₁ 48.9 ± 11.3%pred; FVC 58.8 ± 9.8%pred) | Pulmonary rehabilitation HR of the gas exchange threshold                         | 3 months 3 sessions/week 45 min/session | HR at rest (bpm)                            | Pre 75.6 ± 13.9 vs. Post 76.5 ± 14.0, p > 0.05 ES = 0.06 |
| Camillo et al., 2011    | Randomized controlled trial | 40 patients with COPD High-intensity group: 20 (10♂; 67.0 ± 7.0 years; FEV₁ 40.0 ± 13.0%pred) Low-intensity group: 20 (11♂; 65.0 ± 10.0 years; FEV₁ 39.0 ± 14.0%pred) | High-intensity group: Aerobic and strength training 60% of WRmax 75% of average walking speed in the 6MWT 70% of 1RM Low-intensity group: Strength training | All groups: 12 weeks 3 sessions/week 1 h/session | Standard deviation of N-N intervals (ms) | High-intensity group: Pre 29.0 ± 15.0 vs. Post 36.0 ± 19.0, p < 0.05 ES = 0.41 Low-intensity group: Pre 25.0 ± 12.0 vs. Post 22.0 ± 10.0, p > 0.05 ES = −0.27 |
|                         |                         |                                                                            |                                                                           |                        | Square root of the mean squared difference of the successive N-N intervals (ms) | High-intensity group: Pre 22.0 ± 14.0 vs. Post 28.0 ± 22.0, p < 0.05 ES = 0.33 Low-intensity group: Pre 22.0 ± 22.0 vs. Post 19.0 ± 14.0, p > 0.05 ES = −0.16 |
|                         |                         |                                                                            |                                                                           |                        | Low frequency in supine (%) | High-intensity group: Pre 44.0 ± 15.0 vs. Post 42.0 ± 24.0, p > 0.05 ES = −0.10 Low-intensity group: Pre 48.0 ± 19.0 vs. Post 43.0 ± 19.0, p > 0.05 ES = −0.26 |
|                         |                         |                                                                            |                                                                           |                        | Low frequency in orthostatic (%) | High-intensity group: Pre 55.0 ± 21.0 vs. Post 50.0 ± 20.0, p > 0.05 ES = −0.24 Low-intensity group: Pre 58.0 ± 15.0 vs. Post 62.0 ± 20.0, p > 0.05 ES = 0.23 |
Table 2. Cont.

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|----------------------------------|
|                    |              |            |              |                        | High intensity group: Pre 56.0 ± 15.0 vs. Post 58.0 ± 24.0, \( p > 0.05 \) |                      |
|                    |              |            |              |                        | ES = 0.10                                  | High frequency in supine (%)      |
|                    |              |            |              |                        | Low intensity group: Pre 51.0 ± 19.0 vs. Post 56.0 ± 19.0, \( p > 0.05 \) |                      |
|                    |              |            |              |                        | ES = 0.26                                  | Low frequency group: Pre           |
|                    |              |            |              |                        | ES = 0.10                                  | 44.0 ± 21.0 vs. Post 50.0 ± 20.0, \( p > 0.05 \) |
|                    |              |            |              |                        | ES = 0.29                                  | ES = 0.29                         |
|                    |              |            |              |                        | ES = −0.23                                 | Low frequency group: Pre           |
|                    |              |            |              |                        | ES = −0.23                                 | 41.0 ± 15.0 vs. Post 37.0 ± 20.0, \( p > 0.05 \) |
|                    |              |            |              |                        | ES = −0.23                                 | ES = −0.23                         |
|                    |              |            |              |                        | ES = 0.60                                  | Low frequency/High frequency ratio in supine |
|                    |              |            |              |                        | ES = 0.60                                  | High intensity group: Pre 0.9 ± 0.8 vs. Post 1.3 ± 1.5, \( p > 0.05 \) |
|                    |              |            |              |                        | ES = −0.09                                 | ES = −0.09                         |
|                    |              |            |              |                        | ES = 0.52                                  | Low frequency/High frequency ratio in orthostatic |
|                    |              |            |              |                        | ES = 0.52                                  | High intensity group: Pre 2.3 ± 3.1 vs. Post 1.3 ± 0.9, \( p > 0.05 \) |
|                    |              |            |              |                        | ES = −0.44                                 | ES = −0.44                         |

| Lan et al., 2011 | Non-controlled study | 44 patients with COPD | All groups: Pulmonary rehabilitation 50%–75% of VO2peak All groups: 12 weeks 2 sessions/week 40–50 min/session | HR at rest (bpm) | Underweight group: Pre 85.2 ± 13.0 vs. Post 83.1 ± 11.7, \( p = 0.315 \) |
| Taiwan           |                          | Underweight group: 22 (21♂; 69.1 ± 12.0 years; FEV1 52.8 ± 17.1%pred; FVC 79.5 ± 21.4%pred) | | | ES = −0.17 |
|                   |                          | Non-underweight group: 22 (21♂; 71.4 ± 7.5 years; FEV1 51.5 ± 13.3%pred; FVC 79.1 ± 15.1%pred) | | | Non-underweight group: Pre 88.2 ± 11.6 vs. Post 86.0 ± 10.8, \( p = 0.029 \) |
|                   |                          | All groups: | | | ES = −0.20 |
| Study and Country         | Study Design | Population                                                                 | Intervention                                                                                   | Duration and Frequency            | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|--------------------------|-------------|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|-----------------------------------|---------------------------------------------|-----------------------------------|
| Corhay et al., 2012      | Non-controlled study | 140 patients with COPD <65 years group: 69 (42♂; 57.6 ± 5.2 years; FEV₁ 38.1 ± 10.8%pred) | Cardiovascular disease: n = 19 65–74 years group: 50 (36♂; 69.5 ± 2.6 years; FEV₁ 39.5 ± 11.7%pred) | All groups: Pulmonary rehabilitation 50%–80% of WRmax 60% of maximal walking speed in the 6MWT 50% of IRM | 6 months 2–3 sessions/week 2 h/session |                                    |
| Belgium                  |             |                                                                             | Cardiac outcome: n = 19                                                                  |                                   |                                             |                                    |
|                         |             |                                                                             | ≥75 years group: 21 (17♂; 77.4 ± 2.5 years; FEV₁ 39.9 ± 9.2%pred)                          |                                   |                                             |                                    |
|                         |             |                                                                             | All groups: Pulmonary rehabilitation 50%–80% of WRmax                                      |                                   |                                             |                                    |
|                         |             |                                                                             | HR at rest (bpm) Pre 88.0 ± 10.7 vs. Post 83.3 ± 10.5, p = 0.004 ES = −0.63                |                                   |                                             |                                    |
|                         |             |                                                                             | Oxygen pulse (ml/beat) Pre 9.2 ± 2.5 vs. Post 9.8 ± 2.7, p = 0.02 ES = 0.23               |                                   |                                             |                                    |
|                         |             |                                                                             | HR recovery (bpm) Pre 16.2 ± 8.0 vs. Post 18.4 ± 8.4, p = 0.01 ES = 0.27                   |                                   |                                             |                                    |
| Georgiopoulou et al., 2012 | Pre-Post study | 45 patients with COPD (40♂; 66.5 ± 7.6 years; FEV₁ 45.7 ± 18.7%pred; FVC 78.3 ± 18.6%pred) | Pulmonary rehabilitation 60%–80% of WRmax                                                  | 12 weeks 3 sessions/week 40 min/session |                                             |                                    |
| Greece                   |             |                                                                             | HR (bpm) Pre 134.5 ± 14.9 vs. Post 137.4 ± 19.9, p = 0.36 ES = 0.16                      |                                   |                                             |                                    |
| Lan et al., 2013         | Pre-Post study | 26 patients with COPD (71.0 ± 10.7 years; FEV₁ 64.8 ± 23.0%pred; FVC 88.3 ± 34.5%pred) | Pulmonary rehabilitation 75%–100% of VO2max                                               | 12 weeks 2 sessions/week 40 min/session |                                             |                                    |
| Taiwan                   |             |                                                                             | Mean blood pressure (mmHg) Pre 109.6 ± 15.7 vs. Post 110.3 ± 15.1, p = 0.72 ES = 0.05   |                                   |                                             |                                    |
| Cheng et al., 2014       | Pre-Post study | 64 patients with COPD (55♂; 70.1 ± 8.7 years; FEV₁ 44.9 ± 11.7%pred; FVC 78.2 ± 17.4%pred) | Pulmonary rehabilitation 60%–100% of VO2peak                                               | 12 weeks 2 sessions/week 50 min/session |                                             |                                    |
| Taiwan                   |             |                                                                             | HR at rest (bpm) Pre 87.2 ± 12.7 vs. Post 83.9 ± 13.5, p = 0.048 ES = −0.25              |                                   |                                             |                                    |
|                         |             |                                                                             | Oxygen pulse (ml/beat) Pre 7.2 ± 1.9 vs. Post 7.9 ± 2.2, p = 0.005 ES = 0.34            |                                   |                                             |                                    |
|                         |             |                                                                             | Oxygen pulse (%) Pre 76.8 ± 18.4 vs. Post 85.2 ± 24.8, p = 0.003 ES = 0.38              |                                   |                                             |                                    |
Table 2. Cont.

| Study and Country | Study Design          | Population                                                                 | Intervention                        | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures                                                                 | Results on Cardiovascular Outcomes |
|-------------------|-----------------------|----------------------------------------------------------------------------|-------------------------------------|------------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------|
|                   |                       | 10 patients with COPD (7♂; 67.0 ± 7.0 years; FEV₁ 32.0 ± 11.0%pred; FVC 58.0 ± 15.0%pred) | Aerobic training 70% of peak speed in CPET | 12 weeks 3 sessions/week 30 min/session | Standard deviation of N-N at rest: Pre vs. Post, \( p < 0.05 \)  
At exercise: Pre vs. Post, \( p < 0.05 \) | At rest: Pre vs. Post, \( p < 0.05 \)  
At exercise: Pre vs. Post, \( p < 0.05 \) |
|                   |                       |                                                                           |                                    |                        | Square root of the mean sum of the squares of the difference between adjacent normal R-R intervals at rest: Pre vs. Post, \( p < 0.05 \)  
At exercise: Pre vs. Post, \( p < 0.05 \) | At rest: Pre vs. Post, \( p < 0.05 \)  
At exercise: Pre vs. Post, \( p < 0.05 \) |
|                   |                       |                                                                           |                                    |                        | Low frequency  
Mean of RR and its standard deviation at rest (ms) Pre 17.2 ± 7.3 vs. Post 25.4 ± 5.5, \( p < 0.05 \)  
\( ES = 1.27 \)  
Mean of RR and its standard deviation at constant speed (ms) Pre 12.7 ± 5.1 vs. Post 18.3 ± 4.7, \( p > 0.05 \)  
\( ES = 1.14 \)  
Square root of the mean squared differences of successive RRI at rest (ms) Pre 11.7 ± 6.0 vs. Post 22.9 ± 0.2, \( p < 0.05 \)  
\( ES = 2.64 \)  
Square root of the mean squared differences of successive RRI at constant speed (ms) Pre 3.5 ± 1.7 vs. Post 16.9 ± 7.0, \( p < 0.05 \)  
\( ES = 2.63 \) | Nonlinear indices – SD1 at rest Pre 7.1 ± 4.2 vs. Post 19.2 ± 11.8, \( p < 0.05 \)  
\( ES = 1.37 \) |

Borghi-Silva et al., 2015  
Brazil
Table 2. Cont.

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|-----------------------------------|
| Campos et al., 2015 Chile | Pre-Post study | 39 patients with COPD (36%♂; 67.3 ± 8.5 years; FEV₁ 59.8 ± 21.0%pred; FVC 78.0 ± 20.3%pred) Arterial hypertension: n = 31 Dyslipidemia: n = 5 Congestive heart failure: n = 3 | Pulmonary rehabilitation 70%–80% of 6MWT | 12 weeks 2 sessions/week 90 min/session | Nonlinear indices – SD1 at constant speed | Pre 3.7 ± 1.7 vs. Post 3.6 ± 8.8, p < 0.05 ES = 1.56 |
| Leite et al., 2015 Brazil | Non-randomized controlled trial | 10 patients with COPD (62.0 (60.3; 69.3) years; FEV₁ 55.0 (39.0; 70.0)%pred; FVC 78.0 (66.8; 83.5)%pred) | Aerobic training 60%–100% of VO₂peak | 12 weeks 3 sessions/week 20–50 min/session | Standard deviation of the mean of all normal RR intervals (ms) | Pre 19.8 ± 6.2 vs. Post 24.9 ± 8.6, p > 0.05 ES = 0.67 |
| | | | | | Root mean square of differences between adjacent normal RR intervals in a time interval (ms) | Pre 14.2 ± 5.7 vs. Post 18.3 ± 6.2, p < 0.05 ES = 0.69 |
| | | | | | Spectral component of low frequency (ms²) | Pre 146.1 ± 118.9 vs. Post 177.7 ± 125.6, p > 0.05 ES = 0.26 |
| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|---------------------------------|
| Mkacher et al., 2015 | Randomized controlled trial | 68 patients with COPD Pulmonary rehabilitation group: 33 (33♂; 61.2 ± 3.2 years; FEV1 38.6 ± 8.6%pred) Pulmonary rehabilitation+balance group: 35 (35♂; 58.3 ± 4.3 years; FEV1 39.4 ± 10.3%pred) | All groups: Pulmonary rehabilitation | All groups: 6 months 6 sessions/week (3 times/week, 2 sessions/day) | Spectral component of low frequency (nu) Pre 67.5 ± 16.0 vs. Post 58.5 ± 13.6, p > 0.05 ES = −0.61 |
| Spielmanns et al., 2015 | Randomized controlled trial | 36 patients with COPD Compressed air group: 17 (64.0 ± 8.4 years; FEV1 43.0 ± 12.0%pred) Arterial hypertension: n = 7 Cardiovascular disease: n = 2 Oxygen group: 19 (65.0 ± 8.7 years; FEV1 44.0 ± 10.0%pred) Arterial hypertension: n = 8 Cardiovascular disease: n = 4 | All groups: Continuous aerobic training 70%–85% of WRmax Interval aerobic training 110%–125% of WRmax | All groups: 24 weeks 3 sessions/week 30 min/session | Spectral component of high frequency (ms²) Pre 62.3 ± 46.8 vs. Post 113.2 ± 62.2, p < 0.05 ES = 0.92 |
| Cardoso et al., 2016 | Non-randomized controlled trial | 10 patients with COPD (65.2 ± 4.2 years; FEV1 41.8 ± 21.3%pred; FVC 60.7 ± 18.0%pred) Arterial hypertension: n = 7 | Pulmonary rehabilitation 75% of WRmax 60% of 1RM | All groups: 12 weeks 3 sessions/week >30 min/session | Spectral component of high frequency (nu) Pre 32.6 ± 15.9 vs. Post 41.5 ± 13.6, p > 0.05 ES = 0.60 |
|                   |              |            |              |                        | Low frequency/High frequency ratio Pre 2.9 ± 2.2 vs. Post 1.6 ± 0.8, p > 0.05 ES = −0.78 | Pulmonary rehabilitation group: Pre 72.7 ± 8.9 vs. Post 73.0 ± 4.3, p > 0.05 ES = 0.04 Pulmonary rehabilitation+balance group: Pre 75.3 ± 4.5 vs. Post 73.5 ± 3.9, p > 0.05 ES = −0.43 |
| Study and Country         | Study Design          | Population                                                                 | Intervention                                      | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures                                      | Results on Cardiovascular Outcomes                   |
|--------------------------|-----------------------|----------------------------------------------------------------------------|--------------------------------------------------|------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------|
| Engel et al., 2016       | Randomized controlled | 33 patients with COPD (10♂; 65.5 ± 4.0 years; FEV₁ 1.6 ± 0.5 L; FVC 2.3 ± 0.7 L) | Pulmonary rehabilitation                          | 16 weeks               | Systolic blood pressure (mmHg)                                                      | Mean Pre/Post difference Group 1: −3.6, 95% CI (−13.5; 6.3) Group 2: −10.6, 95% CI (−19.6; −1.5) Group 3: −8.3, 95% CI (−20.5; 3.8) |
| Boeselt et al., 2017     | Non-randomized        | 20 patients with COPD (16♂; 65.9 ± 8.2 years; FEV₁ 67.9 ± 29.2%pred) Arterial hypertension: n = 5 Cardiovascular disease: n = 2 | Strength training 35%–75% of 1RM                   | 3 months               | Diastolic blood pressure (mmHg)                                                    | Mean Pre/Post difference Group 1: −3.5, 95% CI (−12.6; 5.6) Group 2: −7.7, 95% CI (−17.1; 1.8) Group 3: −4.7, 95% CI (−13.5; 4.2) |
| Kanao et al., 2017       | Pre-Post study        | 29 patients with COPD (26♂; 73.2 ± 5 years; FEV₁ 51.0 ± 121.3%pred) Arterial hypertension: n = 10 Cardiovascular disease: n = 5 | Pulmonary rehabilitation 60% of WRpeak            | 12 weeks               |                                                                                  |                                                     |
| Pacheco et al., 2017     | Observational study   | 35 patients with COPD (88.6%♂; 65.1 ± 9.0 years; FEV₁ 42.2 ± 10.5; FVC 67.8 ± 13.3%pred; DLCO 47.9 ± 21.0%pred Arterial hypertension: n = 20 Dyslipidemia: n = 6 Congestive heart failure: n = 7 Ischemic cardiomyopathy: n = 3 | Pulmonary rehabilitation 70% of WRmax 75% of 1RM | 12 weeks               |                                                                                  |                                                     |
### Table 2. Cont.

| Study and Country | Study Design                  | Population                                                                 | Intervention                      | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|-------------------------------|----------------------------------------------------------------------------|-----------------------------------|------------------------|---------------------------------------------|-----------------------------------|
| Papp et al., 2017 | Sweden Randomized controlled trial | 17 patients with COPD (7♂; 69.0 (62.0; 72.1) years; FEV<sub>1</sub> 64.3 ± 15.4%pred) | Aerobic and strength training 70% of 1RM Perceived exertion 12–14 in the Borg | 12 weeks 2 sessions/week 60–70 min/session | HR at rest (bpm) | Mean Pre/Post difference 0.6, p = 0.82 |
|                   |                               |                                                                            |                                   |                        | Systolic blood pressure at rest (mmHg) | Mean Pre/Post difference 4.2 |
|                   |                               |                                                                            |                                   |                        | Diastolic blood pressure at rest (mmHg) | Mean Pre/Post difference 5.7, p = 0.04 |
|                   |                               |                                                                            |                                   |                        | Number of pairs of adjacent NN intervals differing by more than 50 ms in the 5 min recording divided by the total number of all NN intervals (%) | Mean Pre/Post difference 0.6, p = 0.56 |
|                   |                               |                                                                            |                                   |                        | Square root of the mean of the sum of the squares of differences between adjacent NN intervals | Mean Pre/Post difference −3.2, p = 0.27 |
| Vasilopoulou et al., 2017 | Greece Randomized controlled trial | 50 patients with COPD (38♂; 66.7 ± 7.3 years; FEV<sub>1</sub> 51.8 ± 17.3%pred; FVC 78.4 ± 18.4%pred; DLCO 57.0 ± 20.4%pred) Cardiovascular disease: n = 15 | Pulmonary rehabilitation | 12 months 2 sessions/week | HR at rest Pre vs. Post p > 0.05 |
|                   |                               |                                                                            |                                   |                        | Mean blood pressure at rest Pre vs. Post p < 0.05 |
|                   |                               |                                                                            |                                   |                        | Oxygen pulse Pre vs. Post p < 0.05 |
| Lan et al., 2018 | Taiwan Pre-Post study          | 45 patients with COPD (31♂; 69.7 ± 8.8 years; FEV<sub>1</sub> 49.5 ± 19.9%pred; FVC 76.5 ± 22.3%pred) | Pulmonary rehabilitation | 12 weeks 2 sessions/week 40 min/session | HR at rest Pre vs. Post p < 0.05 |
| Moezy et al., 2018 | Iran Randomized controlled trial | 14 patients with COPD (71.4%♂; 64.7 ± 7.5 years; FEV<sub>1</sub> 60.2 ± 14.0%pred) | Aerobic training Dyspnoea 3–4 in the mBorg | 12 weeks 3 sessions/week 15–60 min/session | HR at rest (bpm) Pre 80.4 ± 12.6 vs. Post 77.8 ± 11.9, p = 0.968 E5 = −0.21 |
| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|-----------------------------------------------|---------------------------------|
| Silva et al., 2018  | Randomized controlled trial | 48 patients with COPD | Elastic resistances group: 32 (69.4 ± 9.0 years; FEV₁ 50.7 ± 16.7%pred; FVC 72.5 ± 13.2%pred) | All groups: Strength training | All groups: 12 weeks 3 sessions/week 60 min/session | Total cholesterol (mg/dL) | Elastic resistances group: Pre 108.4 ± 25.3 vs. Post 104.6 ± 14.3, p > 0.05 ES = −0.18 Weight machines group: Pre 84.6 ± 27.0 vs. Post 71.1 ± 32.0, p > 0.05 ES = −0.46 |
| Charikiopoulou et al., 2019  | Non-controlled study | 32 patients with COPD (25♂; 66.0 ± 6.0 years; FEV₁ 43.1 ± 15.1%pred; DLCO 38.2 ± 22.8%pred) | Pulmonary rehabilitation 100% of WRmax | 13 weeks 2 sessions/week ≥1 h/session | Total cholesterol (mg/dL) | Elastic resistances group: Pre 154.2 ± 62.3 vs. Post 129.7 ± 40.3, p > 0.05 ES = −0.47 Weight machines group: Pre 104.8 ± 38.4 vs. Post 99.9 ± 32.9, p > 0.05 ES = −0.14 |
| Charikiopoulou et al., 2019  | Non-controlled study | 32 patients with COPD (25♂; 66.0 ± 6.0 years; FEV₁ 43.1 ± 15.1%pred; DLCO 38.2 ± 22.8%pred) | Cardiovascular disease; n = 22 | Pulmonary rehabilitation 100% of WRmax | 13 weeks 2 sessions/week ≥1 h/session | Total cholesterol/HDL ratio (mg/dL) | Elastic resistances group: Pre 50.7 ± 39.9 vs. Post 40.9 ± 25.8, p > 0.05 ES = −0.29 Weight machines group: Pre 71.9 ± 51.2 vs. Post 61.3 ± 15.4, p > 0.05 ES = −0.43 |
| Study and Country       | Study Design                  | Population                                                                 | Intervention                                                                 | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|------------------------|-------------------------------|----------------------------------------------------------------------------|--------------------------------------------------------------------------------|------------------------|-----------------------------------------------|-----------------------------------|
| Mekki et al., 2019     | Randomized controlled trial   | 45 patients with COPD                                                      | Pulmonary rehabilitation+NMES group: 25 (25♂; 59.6 ± 4.8 years; FEV₁ 57.7 ± 14.4%pred; FVC 76.0 ± 13.2%pred) | All groups:            | HR at rest (bpm)                              | Pulmonary rehabilitation+NMES group: Pre 80.0 ± 9.0 vs. Post 78.0 ± 9.0, \( p < 0.001 \) \( ES = -0.22 \) |
|                        |                               | Pulmonary rehabilitation 60%–70% of HRmax in the 6MWT 50%–85% of 10RM        | All groups: Pulmonary rehabilitation 60%–70% of HRmax in the 6MWT 50%–85% of 10RM | All groups:            |                                               |                                    |
|                        |                               |                                                                            | All groups: 6 months 3 sessions/week 80 min/session                          |                        |                                               |                                    |
|                        |                               |                                                                            | 6 months 3 sessions/week 80 min/session                                       |                        |                                               |                                    |
|                        |                               |                                                                            | 6 months 3 sessions/week 80 min/session                                       |                        |                                               |                                    |
|                        |                               |                                                                            | HR at rest (bpm)                              | Pulmonary rehabilitation+NMES group: Pre 80.0 ± 9.0 vs. Post 78.0 ± 9.0, \( p < 0.001 \) \( ES = -0.22 \) |                                    |
|                        |                               |                                                                            | 6 months 3 sessions/week 80 min/session                                       |                        |                                               |                                    |
|                        |                               |                                                                            | HR (bpm)                              | Elastic resistances group: Pre 74.1 ± 8.8 vs. Post 76.8 ± 8.9, \( p > 0.05 \) \( ES = 0.30 \) | Elastic resistances group: Pre 74.1 ± 8.8 vs. Post 76.8 ± 8.9, \( p > 0.05 \) \( ES = 0.30 \) |
|                        |                               |                                                                            | HR (bpm)                              | Weight machines group: Pre 71.4 ± 6.4 vs. Post 68.9 ± 9.9, \( p > 0.05 \) \( ES = -0.30 \) | Weight machines group: Pre 71.4 ± 6.4 vs. Post 68.9 ± 9.9, \( p > 0.05 \) \( ES = -0.30 \) |
|                        |                               |                                                                            | Systolic blood pressure (mmHg)                          | Elastic resistances group: Pre 121.0 (105.0; 135.0) vs. Post 120.0 (110.0; 120.0), \( p > 0.05 \) | Elastic resistances group: Pre 121.0 (105.0; 135.0) vs. Post 120.0 (110.0; 120.0), \( p > 0.05 \) |
|                        |                               |                                                                            | Systolic blood pressure (mmHg)                          | Weight machines group: Pre 121.0 (117.5; 130.0) vs. Post 120.0 (110.0; 120.0), \( p > 0.05 \) | Weight machines group: Pre 121.0 (117.5; 130.0) vs. Post 120.0 (110.0; 120.0), \( p > 0.05 \) |
|                        |                               |                                                                            | Diastolic blood pressure (mmHg)                        | Elastic resistances group: Pre 70.0 (70.0; 80.0) vs. Post 70.0 (70.0; 75.0), \( p > 0.05 \) | Elastic resistances group: Pre 70.0 (70.0; 80.0) vs. Post 70.0 (70.0; 75.0), \( p > 0.05 \) |
|                        |                               |                                                                            | Diastolic blood pressure (mmHg)                        | Weight machines group: Pre 80.0 (70.0; 90.0) vs. Post 75.0 (67.5; 80.0), \( p > 0.05 \) | Weight machines group: Pre 80.0 (70.0; 90.0) vs. Post 75.0 (67.5; 80.0), \( p > 0.05 \) |

Data are presented as mean ± standard deviation or median (interquartile range), unless otherwise stated. Legend: 6MWT, 6-min walk test; 12MWT, 12-min walk test; 1RM, one repetition maximum; 10RM, ten repetition maximum; 15RM, fifteen repetition maximum; 95%CI, 95% confidence interval; %pred, percentage predicted; COPD, chronic obstructive pulmonary disease; CPET, cardiopulmonary exercise test; DLCO, diffusing capacity for carbon monoxide; ES, effect size; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; HDL, high density lipoprotein; HR, heart rate; HRmax, maximum heart rate; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; LDL, low density lipoprotein; mBorg, modified Borg scale; NMES, neuromuscular electrical stimulation; VO₂max, maximal oxygen uptake; VO₂peak, peak oxygen uptake; WR, work rate; WRmax, maximal work rate; WRpeak, peak work rate.
Table 3. Characteristics of the studies in patients with asthma included in phase 2 (i.e., studies that specified the prevalence of cardiovascular comorbidities in the baseline characteristics of the population under study and/or reported at least one cardiovascular outcome) \((n = 2)\).

| Study and Country       | Study design               | Population                                                                 | Intervention                                                         | Duration and Frequency | Cardiovascular Outcomes and Outcome measures | Results on Cardiovascular Outcomes |
|-------------------------|----------------------------|----------------------------------------------------------------------------|----------------------------------------------------------------------|------------------------|---------------------------------------------|-----------------------------------|
| Cochrane et al., 1990   | Randomized controlled trial| 18 patients with Asthma \((27.0 \pm 17.0\) years; \(\text{FEV}_1\) 76.0 \pm 12.0\%pred) | Aerobic and muscle strength training 75\% of HRmax                   | 3 months               | Oxygen pulse \((\text{mL/beat})\)             | Pre 8.8 \pm 2.3 vs. Post 10.8 \pm 2.4, \(p < 0.001\) \(ES = 0.85\) |
| Scotland                |                            |                                                                            |                                                                      | 3 sessions/week        | Total blood cholesterol \((\text{mmol/L})\)     | Pre 5.4 \pm 1.1 vs. Post 5.3 \pm 1.1, \(p > 0.05\) \(ES = -0.09\) |
|                         |                            |                                                                            |                                                                      | 30 min/session         | Cholesterol – HDL \((\text{mmol/L})\)           | Pre 1.7 \pm 0.4 vs. Post 1.6 \pm 0.3, \(p > 0.05\) \(ES = -0.28\) |
|                         |                            |                                                                            |                                                                      |                        | Cholesterol – LDL \((\text{mmol/L})\)          | Pre 3.2 \pm 1.2 vs. Post 2.9 \pm 0.9, \(p > 0.05\) \(ES = -0.28\) |
|                         |                            |                                                                            |                                                                      |                        | Cholesterol – Triglycerides \((\text{mg/dL})\)  | Pre 34.7 \pm 5.6 vs. Post 37.9 \pm 4.6, \(p < 0.05\) \(ES = 0.62\) |
| El-Kader et al., 2016   | Randomized controlled trial| 40 patients with Asthma \((23\%); 47.2 \pm 6.5\) years; \(\text{FEV}_1\) 1.4 \pm 0.7 L) | Aerobic training 60–80\% of HRmax                                   | 6 months               | Cholesterol – HDL \((\text{mg/dL})\)           | Pre 133.7 \pm 13.2 vs. Post 120.3 \pm 11.5, \(p < 0.05\) \(ES = -1.08\) |
| Saudi Arabia            |                            |                                                                            |                                                                      | 3 sessions/week        | Cholesterol – LDL \((\text{mg/dL})\)          | Pre 155.4 \pm 12.6 vs. Post 127.7 \pm 11.3, \(p < 0.05\) \(ES = -2.31\) |
|                         |                            |                                                                            |                                                                      | 30 min/session         | Cholesterol – Triglycerides \((\text{mg/dL})\)  |                                                                      |

Data are presented as mean \(\pm\) standard deviation, unless otherwise stated. Legend: %pred, percentage predicted; ES, effect size; \(\text{FEV}_1\), forced expiratory volume in 1 s; HDL, high density lipoprotein; HR, heart rate; \(\text{HR}_{\text{max}}\), maximum heart rate; LDL, low density lipoprotein.
**Table 4.** Characteristics of the studies in patients with ILD included in phase 2 (i.e., studies that specified the prevalence of cardiovascular comorbidities in the baseline characteristics of the population under study and/or reported at least one cardiovascular outcome) (*n* = 8).

| Study and Country             | Study Design     | Population                                                                 | Intervention                                                      | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes                                                                 |
|-------------------------------|------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------|------------------------|---------------------------------------------|---------------------------------------------------------------------------------------------------|
| Gaunaud et al., 2014 United States of America | Randomized controlled trial | 11 patients with IPF (71.0 ± 6.0 years; FVC 60.0 ± 11.0%pred; DLCO 44.0 ± 11.0%pred) | Pulmonary rehabilitation 70%–80% of HRmax | 12 weeks | HR at rest (bpm) | Mean Pre/Post difference | Pre 82.7 ± 13.1 vs. Post 77.1 ± 12.8, *p* = 0.04 ES = −0.43 |
| Vainshelboim et al., 2014 Israel | Randomized controlled trial | 15 patients with IPF (70.0 ± 6.0 years; FEV1 68.5 ± 15.8%pred; FVC 66.1 ± 14.8%pred; DLCO 48.6 ± 17.2%pred) | Aerobic and strength training 50%–70% of WRpeak 70%–90% of average walking speed in the 6MWT 3–6 in the mBorg | 12 weeks | HR at rest (bpm) | Mean Pre/Post difference | Pre vs. Post, *p* > 0.05 |
| Marcellis et al., 2015 The Netherlands | Pre-Post study | 18 patients with Sarcoidosis (50.3 ± 10.4 years; FEV1 93.6 ± 17.0%pred; FVC 102.2 ± 18.1%pred; DLCO 91.2 ± 18.4%pred) | Aerobic and strength training 40% of 1RM 60% of maximal walking speed in the 6MWT 50% of WRmax | 13 weeks | HR at rest (bpm) | Mean Pre/Post difference | Pre 82.7 ± 13.1 vs. Post 77.1 ± 12.8, *p* = 0.04 ES = −0.43 |
| Vainshelboim et al., 2015 Israel | Randomized controlled trial | 15 patients with IPF (10♂; 68.8 ± 6 years; FVC 66.1 ± 14.8%pred; DLCO 48.6 ± 17.2%pred) | Aerobic and strength training 50%–70% of WRpeak 70%–90% of average walking speed in the 6MWT Perceived exertion 3–6 in the mBorg | 12 weeks | HR at rest (bpm) | Mean Pre/Post difference | Pre vs. Post, *p* > 0.05 |
| Boström et al., 2016 Sweden | Randomized controlled trial | 18 patients with Systemic lupus erythematosus (5♂; 52.0 ± 10.0 years) | Pulmonary rehabilitation 65%–80% of HRmax Perceived exertion 13–16 in the Borg | 12 weeks | HR at rest | Blood pressure at rest | Pre vs. Post, *p* > 0.05 |
### Table 4. Cont.

| Study and Country        | Study Design                  | Population                                                                 | Intervention                                                                 | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures                                      | Results on Cardiovascular Outcomes                                    |
|--------------------------|-------------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------|
| Vainshelboim et al., 2017| Randomized controlled trial  | 15 patients with IPF (10♂; 68.8 ± 6.0 years; FVC 66.1 ± 14.8%pred; DLCO 48.6 ± 17.2%pred) | Arterial hypertension: n = 12 Coronary heart disease: n = 7 Pulmonary hypertension: n = 5 | 12 weeks 2 sessions/week 60 min/session | HR (bpm) | Mean Pre/Post difference −2.4 ± 9.1 ES = −0.26 | Mean Pre/Post difference 6.7 ± 11.0 ES = 0.61 |
|                          |                               |                                                                             | Aerobic and strength training 50%–70% of WRpeak 70%–90% of average walking speed in the 6MWT |                        | HR reserve (bpm) | Mean Pre/Post difference −2.9 ± 13.6 ES = −0.21 | Mean Pre/Post difference 1.5 ± 7.1 ES = 0.21 |
|                          |                               |                                                                             |                                                                               |                        | Systolic blood pressure (mmHg) | Mean Pre/Post difference 1685.0 ± 3338.0 ES = 0.50 | Mean Pre/Post difference 0.0 ± 0.5 ES = 0.04 |
|                          |                               |                                                                             |                                                                               |                        | Diastolic blood pressure (mmHg) | Mean Pre/Post difference 0.2 ± 2.7 ES = 0.07 | Mean Pre/Post difference 0.1 ± 0.1 ES = 0.30 |
|                          |                               |                                                                             |                                                                               |                        | Rate pressure product (bpm/mmHg) | Mean Pre/Post difference 0.1 ± 0.3 ES = −0.20 | Mean Pre/Post difference −4.5 ± 13.4 ES = −0.34 |
|                          |                               |                                                                             |                                                                               |                        | Left atrium diameter (cm) | Mean Pre/Post difference −0.1 ± 0.3 ES = −0.47 | Mean Pre/Post difference −0.4 ± 0.8 ES = −0.50 |
|                          |                               |                                                                             |                                                                               |                        | Left atrium area (cm²) | Mean Pre/Post difference −0.2 ± 0.3 ES = −0.4 | Mean Pre/Post difference −0.2 ± 0.4 ES = −0.5 |
|                          |                               |                                                                             |                                                                               |                        | Left ventricle posterior wall thickness (cm) | Mean Pre/Post difference 0.1 ± 0.1 ES = 0.60 | |
|                          |                               |                                                                             |                                                                               |                        | Intra-ventricular septum thickness (cm) | Mean Pre/Post difference 0.1 ± 0.1 ES = 0.60 | |
|                          |                               |                                                                             |                                                                               |                        | Left ventricle end systolic diameter index (cm/m²) | Mean Pre/Post difference −0.1 ± 0.3 ES = −0.40 | |
|                          |                               |                                                                             |                                                                               |                        | Left ventricle end diastolic diameter index (cm/m²) | Mean Pre/Post difference −0.1 ± 0.3 ES = −0.40 | |
|                          |                               |                                                                             |                                                                               |                        | Stroke volume (mL/beat) | Mean Pre/Post difference −0.4 ± 0.8 ES = −0.50 | |
|                          |                               |                                                                             |                                                                               |                        | Cardiac output (L/min) | Mean Pre/Post difference −0.4 ± 0.8 ES = −0.50 | |
|                          |                               |                                                                             |                                                                               |                        | Cardiac index (L/min/m²) | Mean Pre/Post difference −0.4 ± 0.8 ES = −0.50 | |
Table 4. Cont.

| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|-------------------|--------------|------------|--------------|------------------------|---------------------------------------------|----------------------------------|
| 1                 |              |            |              |                        | Ejection fraction (%)                        | Mean Pre/Post difference 0.8 ± 3.0  
|                   |              |            |              |                        | E5 = 0.27                                   |                                 |
|                   |              |            |              |                        | Fractioning shortening (%)                  | Mean Pre/Post difference 0.9 ± 6.2  
|                   |              |            |              |                        | E5 = 0.15                                   |                                 |
|                   |              |            |              |                        | Earlier transmitral velocity (E) (ms)        | Mean Pre/Post difference 0.8 ± 16.9  
|                   |              |            |              |                        | E5 = 0.05                                   |                                 |
|                   |              |            |              |                        | Late transmital velocity (A) (ms)            | Mean Pre/Post difference 5.1 ± 20.7  
|                   |              |            |              |                        | E5 = 0.25                                   |                                 |
|                   |              |            |              |                        | E/A ratio                                    | Mean Pre/Post difference 0.0 ± 0.4  
|                   |              |            |              |                        | E5 = 0.00                                   |                                 |
|                   |              |            |              |                        | Isovolumic relaxation time (ms)              | Mean Pre/Post difference 9.1 ± 32.1  
|                   |              |            |              |                        | E5 = 0.28                                   |                                 |
|                   |              |            |              |                        | Deceleration time (ms)                       | Mean Pre/Post difference 11.0 ± 52.7  
|                   |              |            |              |                        | E5 = 0.21                                   |                                 |
|                   |              |            |              |                        | Systolic pulmonary arterial pressure (mmHg)  | Mean Pre/Post difference −0.5 ± 6.8  
|                   |              |            |              |                        | E5 = −0.07                                  |                                 |
|                   |              |            |              |                        | Peak circulatory power (mLO2/kg/min/mmHg)    | Mean Pre/Post difference 490.0 ± 637.0  
|                   |              |            |              |                        | E5 = 0.77                                   |                                 |
|                   |              |            |              |                        | Peak cardiac power output (W)                | Mean Pre/Post difference 0.3 ± 0.3  
|                   |              |            |              |                        | E5 = 0.94                                   |                                 |
|                   |              |            |              |                        | Peak stroke work (mLO2/beat/mmHg)           | Mean Pre/Post difference 221.0 ± 343.0  
|                   |              |            |              |                        | E5 = 0.64                                   |                                 |
| Study and Country | Study Design | Population | Intervention | Duration and Frequency | Cardiovascular Outcomes and Outcome Measures | Results on Cardiovascular Outcomes |
|------------------|-------------|------------|--------------|------------------------|---------------------------------------------|----------------------------------|
| Naz et al., 2018a | Pre-Post study | 14 patients with ILD (5♂; 63.0 (53.0; 70.0) years; FEV₁ 78.0 (69.0; 83.0)%pred; FVC 74.0 (67.0; 78.0)%pred; DLCO 40.0 (19.0; 45.0)%pred) | Aerobic and strength training 80% of peak walking speed in the 6MWT | 12 weeks 2 sessions/week 60–90 min/session | | |
| Turkey           |             | Arterial hypertension: \( n = 7 \) Congestive heart failure: \( n = 2 \) | Dyspnoea and perceived exertion 4–6 in the mBorg | | | |
| Naz et al., 2018b | Randomized controlled trial | 9 patients with Sarcoidosis (33.3%♂; 59.0 (52.0; 64.0) years; FEV₁ 73.0 (65.0; 85.0)%pred; FVC 76.0 (66.0; 90.0)%pred; DLCO 45.0 (36.0; 54.0)%pred) | Aerobic and strength training 80% of the peak speed in the 6MWT Fatigue 4–6 in the mBorg | 12 weeks 2 sessions/week | HR (bpm) | Median Pre/Post difference 0.0 [−6.0; 5.0], \( p > 0.05 \) |
| Turkey           |             | | | | | |

Data are presented as mean ± standard deviation or median (interquartile range), unless otherwise stated. Legend: 6MWT, 6-min walk test; 1RM, one repetition maximum; %pred, percentage predicted; DLCO, diffusing capacity for carbon monoxide; ES, effect size; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; HR, heart rate; HRₘₐₓ, maximum heart rate; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; mBorg, modified Borg scale; WR, work rate; WRₘₐₓ, maximal work rate; WRₚₑᵃᵏ, peak work rate.
Most studies \((n = 20; 71.4\% )\) presented only small to moderate effects in the cardiovascular outcome measures reported. Standard deviation of RR intervals \([49,108] (n = 2; ES = [0.67; 2.64])\) and root mean square of successive RR interval differences \([49,57,108] (n = 3; ES = [0.69; 2.64])\) were the outcome measures presenting the larger effects. In patients with COPD, the effects of exercise training programmes on resting heart rate resulted in an overall pooled \(ES\) of \(-0.23\) (95% confidence interval \(-0.33\) to \(-0.13\)) (Figure 5).

**Figure 5.** Forest plot of comparison control versus intervention in patients with COPD; outcome: resting heart rate. \(ES\), effect size; NMES, neuromuscular electrical stimulation; PR, pulmonary rehabilitation.

Regarding the exercise programmes, most studies conducted in patients with COPD performed a pulmonary rehabilitation programme \([33,54,55,57,59,68,80,90,101,104,106,107,121,123,136,167]\) \((n = 16)\) or an exercise programme combining aerobic and strength training \([38,43–45,54,86,129,130]\) \((n = 8)\). Sessions were conducted 2–6 times per week and each session lasted from 15 min to 2 h. Programme duration varied between 12 weeks and 18 months. A wide range of intensities was used to prescribe the exercise: 60%–80% of the maximum heart rate, 50%–100% of the peak or maximum oxygen uptake, 50%–125% of the peak or maximum workload, 35%–75% of one-repetition maximum, dyspnoea and perceived exertion levels between 3–6 on the modified Borg scale and 12–16 on the Borg scale. None of the studies specified any adjustments to tailor the exercise programmes to patients’ cardiovascular comorbidities. Only one study \([108]\) described adjusting the training programme in different mesocycles in order to improve specific cardiovascular outcomes.

Studies conducted in patients with asthma performed either an exercise programme combining aerobic and strength training for 3 months \([189]\) or aerobic training for 6 months \([186]\). Sessions occurred 3 times/week, for 30 min each, at an intensity of 60%–80% of the maximum heart rate. No specific adjustments to improve specific cardiovascular outcomes were reported.

In patients with ILD, most studies conducted exercise programmes combining aerobic and strength training \([201–203,207–209]\) \((n = 6)\). The majority of programmes lasted for 12 weeks with 2 sessions/week \([196,198,202,203,207–209]\) \((n = 7)\). Sessions had a duration of 60–90 min and exercise was prescribed at an intensity of 65%–85% of maximum heart rate, 50%–90% of peak workload, dyspnoea and perceived exertion levels between 3 and 6 on the modified Borg scale. None of the studies specified any adjustments to tailor the exercise programmes to patients’ cardiovascular comorbidities.

4. Discussion

To the best of the authors’ knowledge, this is the first comprehensive overview of the scientific literature summarizing (i) the eligibility criteria in terms of cardiovascular disease used to select patients with chronic respiratory disease to exercise training studies, (ii) the impact of at least 3 months of exercise training on cardiovascular outcomes, and (iii) adjustments made to tailor exercise training prescription to patients with cardiovascular comorbidities. It was found that (i) in the majority of the
studies (58.9%) patients with cardiovascular comorbidities were excluded a priori, (ii) there is limited evidence about the impact of exercise training on cardiovascular outcomes in patients with chronic respiratory diseases, and (iii) none of the studies explicitly mentioned how to tailor exercise training modalities in light of cardiovascular comorbidities.

A large diversity was found regarding the cardiovascular conditions that are used as exclusion criteria in exercise-related research. Interestingly, the majority of the exclusion criteria reported (34/45) are not considered contraindications to exercise training. Indeed, just a minority of the studies (18.3%) excluded only patients with acute/unstable cardiovascular disease that contraindicated participation in exercise training. Most studies excluded patients with both stable and unstable cardiovascular comorbidities, although at least 20%–50% of the patients with COPD, asthma or ILD present cardiovascular comorbidities [5,7,18,20,210,211]. Thus, by excluding patients with cardiovascular comorbidities or any other comorbidity that does not present any contraindication to perform exercise training, translation of knowledge to clinical practice can only be done for a subset, or sometimes even a minority, of patients. This finding might have a far-reaching consequence, namely that current knowledge (including clinical guidelines) is disease-centred and, thus, inadequate to sufficiently support/guide clinicians on how to prescribe exercise for patients with chronic respiratory diseases and multiple chronic conditions [13,212]. Furthermore, some of the criteria reported (e.g., cardiovascular disease) were too vague to allow understanding of which conditions were really excluded and over 20% of the included studies did not report any information concerning to eligibility criteria, even though this is key information to ensure clarity and transparency of the research [213].

Exercise training programmes in patients with cardiovascular comorbidities resulted in significant improvements in general reported outcomes, namely symptoms, functionality, exercise capacity, muscle strength and health-related quality of life, comparable to the ones usually found in respiratory patients [22]. However, regarding cardiovascular outcomes, in the majority of the studies (71.4%) only small to moderate effects were found, with the larger effects being reported for heart rate variability measurements (ES = [−0.78; 2.64]) and blood lipid profile (ES = [−2.31; 0.62]). Additionally, a small but significant overall effect of exercise training programmes on resting heart rate of patients with COPD was found. These results are yet not inferior to the ones previously reported for patients with cardiovascular diseases, in whom beneficial effects of exercise training have been found for heart rate variability and heart rate recovery [214], and inconsistent but significant and modest effects have been reported for arterial blood pressure and blood lipid profile [214–217]. We hypothesized that several reasons might be contributing to the limited effects found. First, most studies have not reported any specific adjustments in the exercise prescription to tailor the programme to patients’ cardiovascular comorbidities, although it is plausible that they have made some adjustments without specific reporting in the published paper. It is known that cardiovascular conditions require specific considerations when formulating the exercise plan [22], and different recommendations exist based on the prevalent cardiovascular disease (e.g., coronary artery disease, congestive heart failure, peripheral arterial disease, pulmonary arterial hypertension) and its severity [218]. Indeed, it is mandatory to tailor exercise duration, frequency, mode, intensity and monitoring to patients’ specificities and needs, clinical conditions, cardiovascular phenotype (risk factors and diseases), fitness level, medication intake (beta blockers, statins, glinides, sulfonylurea), abnormal responses to exercise (myocardial ischemia, atrial fibrillation, ventricular tachycardia) and rehabilitation goals [1,218–221]. Moreover, the impact of exercise training relies on this proper tailoring of the exercise programme, since it has been shown that different exercise prescriptions result in significant differences in clinical outcomes [221]. Future studies should therefore assess the impact of exercise programmes specifically tailored to patients with co-occurring respiratory disease and cardiovascular comorbidities [7] and report the intervention in detail. Second, guidelines for cardiac rehabilitation from the leading scientific societies recommend that exercise should progress from moderate to vigorous intensity, three times per week [21]. Nevertheless, in some of the included studies, patients exercised at lower intensities and/or fewer times per week, which might have also contributed to the relative lack of effects since the minimum
dose of exercise for cardiovascular benefits (>150 min/week of endurance training, energy expenditure 1000–2000 kcal/week) might have not been reached [218,222]. Third, some of the included studies only used strength training in their exercise programmes. Indeed, strength training has been recommended in patients with cardiovascular diseases, but as an adjunct to aerobic training, the last being a core component in these patients’ rehabilitation [21]. From these observations, it became clear that current exercise prescription to patients with COPD, asthma or ILD with cardiovascular comorbidities is far from optimal and deserves significant reconsideration. Nonetheless, digital support on how to prescribe exercise in these patients in accordance to all the different clinical guidelines for different cardiovascular diseases is available, and thus could be used to support health professionals [218]. Lastly, most studies including patients with cardiovascular comorbidities only focused on the assessment of resting heart rate. Although this is a relevant outcome measure and results from meta-analysis in patients with COPD favour intervention, recommendations for patients with cardiovascular diseases advocate a more comprehensive assessment, including outcomes such as arterial blood pressure, blood lipid profile or echocardiography, that are also more in line with the aims of rehabilitation in these patients [223,224]. Therefore, outcomes should be better targeted to patients’ cardiovascular comorbidities [19].

Besides the known prevalence and increased risk of morbidity and mortality that cardiovascular comorbidities impose on patients with chronic respiratory diseases [7,211], only three studies [196,207,209] (all conducted in the last 5 years) included patients with cardiovascular comorbidities and assessed cardiovascular outcome measures. This denotes the current gap in the literature regarding exercise programmes and emphasises the need for specific studies focusing on cardiovascular outcomes in these patients.

This systematic review has a number of limitations that need to be acknowledged. First, as it was anticipated that a large number of studies would be found, only exercise programmes lasting at least 12 weeks were included, which might have led to the loss of other relevant studies. Nevertheless, 12 weeks has been recommended as the minimum exercise duration required to reach benefits in patients with cardiovascular disease [25]. Second, as only few studies including patients with ILD were found, all types of ILD were grouped, although different types of ILD present different characteristics and possibly different cardiovascular comorbidities and responses to exercise training programmes. Third, most of the included studies were of weak quality. Nonetheless, since in exercise interventions blinding of participants is impossible and patients are usually referred by physicians to ensure their safety, it was virtually impossible to ensure strong quality in the quality assessment tool used.

5. Conclusions

Although a large number of studies explored the effects of at least 3 months of exercise training in patients with chronic respiratory diseases, only few included patients with cardiovascular comorbidities. Limited effects of the exercise programmes were found on cardiovascular outcome measures, possibly due to the lack of tailoring of the exercise training prescription and comprehensiveness of the cardiovascular outcome measures. Future studies focusing on patients with combined respiratory and cardiovascular diseases and exploring the effects of exercise programmes specifically tailored to these patients are needed to bridge the gap in the literature.

Author Contributions: All authors made substantial contributions to the concept and design of the work and approved the submitted version (conceptualization, D.H. and C.B.; methodology, A.M., K.Q. and C.B.; formal analysis, A.M.; investigation, A.M., K.Q. and A.O.; data curation, A.M., K.Q. and A.O.; writing—original draft preparation, A.M.; writing—review and editing, K.Q., A.O., C.K., A.M., D.H., C.B.; supervision, C.B.; project administration, C.B.).

Funding: This research received no external funding.

Acknowledgments: We acknowledge the support of the European Respiratory Society – ERS Short-Term Research Fellowship October 2018 (STRTF201810-00469).

Conflicts of Interest: The authors declare no conflict of interest.
Appendix A  Search Strategy

A1. PubMed

#1 Search (“chronic obstructive pulmonary disease” OR “copd” OR “asthma” OR “interstitial lung disease” OR “ILD” OR “parenchymal lung disease” OR “parenchymal lung disorder” OR “pulmonary fibrosis” OR “sarcoidosis” OR “interstitial pneumonia” OR “connective tissue disease” OR “collagen vascular disease” OR “occupational lung disease” OR “hypersensitivity pneumonitis” OR “asbestosis” OR “silicosis” OR “beryliosis” OR “respiratory bronchiolitis” OR “desquamative interstitial pneumonia” OR “cryptogenic organizing pneumonia” OR “lymphoid interstitial pneumonia” OR “pleuroparenchymal fibroelastosis” OR “pneumoconiosis” OR “extrinsic allergic alveolitis” OR “iatrogenic interstitial lung disease” OR “post-infectious interstitial lung disease” OR “granulomatose” OR “systemic sclerosis” OR “polymyositis” OR “dermatomyositis” OR “systemic lupus erythematosus” OR “Hamman-Rich syndrome” OR “bagassosis” OR “histiocytosis” OR “fibrotic interstitial lung disease” OR “fibrotic lung disease”)

#2 Search (“exercise” OR “walking” OR “aerobic training” OR “endurance training” OR “interval training” OR “high-intensity training” OR “resistance training” OR “strength training”)

#3 Search (Pulmonary Disease, Chronic Obstructive” OR “Asthma” OR “Lung Diseases, Interstitial” OR “Pulmonary Fibrosis” OR “Sarcoidosis” OR “Connective Tissue Diseases” OR “Alveolitis, Extrinsic Allergic” OR “Asbestosis” OR “Silicosis” OR “Pneumoconiosis” OR “Scleroderma, Systemic” OR “Polymyositis” OR “Dermatomyositis” OR “Systemic Lupus Erythematosus, Systemic” OR “Histiocytosis”)

#4 Search (“exercise” OR “Walking” OR “Endurance Training” OR “Resistance Training”)

#5 Search (#1 AND #2 [Title/Abstract]) OR (#3 AND #4 [MeSH Terms])

A2. Cochrane, Scopus and Web of Science

#1 Search (“chronic obstructive pulmonary disease” OR copd OR asthma OR “interstitial lung disease” OR ILD OR “parenchymal lung disease” OR “parenchymal lung disorder” OR “pulmonary fibrosis” OR sarcoidosis OR “interstitial pneumonia” OR “connective tissue disease” OR “collagen vascular disease” OR “occupational lung disease” OR “hypersensitivity pneumonitis” OR asbestosis or silicosis or beryliosis or “respiratory bronchiolitis” OR “desquamative interstitial pneumonia” OR “cryptogenic organizing pneumonia” OR “lymphoid interstitial pneumonia” OR “pleuroparenchymal fibroelastosis” OR pneumoconiosis OR “extrinsic allergic alveolitis” OR “iatrogenic interstitial lung disease” OR “post-infectious interstitial lung disease” OR granulomatose OR “systemic sclerosis” OR polymyositis OR dermatomyositis OR “systemic lupus erythematosus” OR “Hamman-Rich syndrome” OR bagassosis OR histiocytosis OR “fibrotic interstitial lung disease” OR “fibrotic lung disease”)

#2 Search (“exercise” OR “walking” OR “aerobic training” OR “endurance training” OR “interval training” OR “high-intensity training” OR “resistance training” OR “strength training”)

#3 Search (#1 AND #2)

References

1. Armstrong, M.; Vogiatzis, I. Personalized exercise training in chronic lung diseases. *Respirology* **2019**, *24*, 854–862. [CrossRef] [PubMed]
2. Bousquet, J.; Kiley, J.; Bateman, E.; Viegi, G.; Cruz, A.; Khaltaev, N.; Khaled, N.A.; Baena-Cagnani, C.; Barreto, M.; Billo, N. Prioritised research agenda for prevention and control of chronic respiratory diseases. *Eur. Respir. J.* **2010**, *36*, 995–1001. [CrossRef] [PubMed]
3. Prince, M.J.; Wu, F.; Guo, Y.; Robledo, L.M.G.; O’Donnell, M.; Sullivan, R.; Yusuf, S. The burden of disease in older people and implications for health policy and practice. *Lancet* **2015**, *385*, 549–562. [CrossRef]
4. World Health Organization. *Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016*; WHO: Geneva, Switzerland, 2018.
5. Mannino, D.M.; Thorn, D.; Swensen, A.; Holguin, F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. *Eur. Respir. J.* 2008, 32, 962–969. [CrossRef] [PubMed]

6. Boulet, L.-P.; Boulay, M.-È. Asthma-related comorbidities. *Expert Rev. Respir. Med.* 2011, 5, 377–393. [CrossRef] [PubMed]

7. Franssen, F.M.; Rochester, C.L. Comorbidities in patients with COPD and pulmonary rehabilitation: Do they matter? *Eur Respir. Soc* 2014, 23, 131–141. [CrossRef] [PubMed]

8. Houben-Wilke, S.; Spruit, M.A.; Uszko-Lencer, N.H.; Otkinska, G.; Vanfleteren, L.E.; Jones, P.W.; Wouters, E.F.; Franssen, F.M. Echocardiographic abnormalities and their impact on health status in patients with COPD referred for pulmonary rehabilitation. *Respirology* 2017, 22, 928–934. [CrossRef]

9. Hylgaard, C.; Hilberg, O.; Bendstrup, E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? *Respir. Med.* 2014, 108, 647–653. [CrossRef]

10. King, C.; Nathan, S.D. Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. *Curr. Opin. Pulm. Med.* 2013, 19, 466–473. [CrossRef]

11. Soriano, J.B.; Visick, G.T.; Muellerova, H.; Payvandi, N.; Hansell, A.L. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. *Chest* 2005, 128, 2099–2107. [CrossRef]

12. Triest, F.J.; Singh, S.J.; Vanfleteren, L.E. Cardiovascular risk, chronic obstructive pulmonary disease and pulmonary rehabilitation: Can we learn from cardiac rehabilitation? *Chronic Respir. Dis.* 2016, 13, 286–294. [CrossRef] [PubMed]

13. Houben-Wilke, S.; Triest, F.J.; Franssen, F.M.; Janssen, D.J.; Wouters, E.F.; Vanfleteren, L.E. Revealing methodological challenges in chronic obstructive pulmonary disease studies assessing comorbidities: A narrative review. *Chronic Obstr. Pulm. Dis. J. Copd. Found.* 2019, 6, 166. [CrossRef] [PubMed]

14. Divo, M.; Cote, C.; de Torres, J.P.; Casanova, C.; Marin, J.M.; Pinto-Plata, V.; Zulueta, J.; Cabrera, C.; Zagaceta, J.; Hunninghake, G. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2012, 186, 155–161. [CrossRef] [PubMed]

15. Kreuter, M.; Ehlers-Tenenbaum, S.; Palmowski, K.; Bruhwylher, J.; Oltmanns, U.; Muley, T.; Heussel, C.P.; Warth, A.; Kolb, M.; Herth, F.J. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. *PLoS ONE* 2016, 11, e0151425. [CrossRef] [PubMed]

16. Miller, J.; Edwards, L.D.; Agusti, A.; Bakke, P.; Calverley, P.M.; Celli, B.; Coxson, H.O.; Crim, C.; Lomas, D.A.; Miller, B.E. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. *Respir. Med.* 2013, 107, 1376–1384. [CrossRef] [PubMed]

17. Terzano, C.; Conti, V.; Di Stefano, F.; Petroiani, A.; Ceccarelli, D.; Graziani, E.; Mariotta, S.; Ricci, A.; Vitarelli, A.; Puglisi, G. Comorbidity, hospitalization, and mortality in COPD: Results from a longitudinal study. *Lung* 2010, 188, 321–329. [CrossRef] [PubMed]

18. Cazzola, M.; Calzetta, L.; Bettoncelli, G.; Cricelli, C.; Romeo, F.; Matera, M.G.; Rogliani, P. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. *Respir. Med.* 2012, 106, 249–256. [CrossRef]

19. Crisafulli, E.; Costi, S.; Luppi, F.; Cirelli, G.; Cilione, C.; Coletti, O.; Fabbri, L.M.; Clini, E.M. Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. *Thorax* 2008, 63, 487–492. [CrossRef]

20. Margaritopoulos, G.A.; Antoniou, K.M.; Wells, A.U. Comorbidities in interstitial lung diseases. *Eur. Respir. Rev.* 2017, 26, 160027. [CrossRef]

21. Price, K.J.; Gordon, B.A.; Bird, S.R.; Benson, A.C. A review of guidelines for cardiac rehabilitation exercise programmes: Is there an international consensus? *Eur. J. Prev. Cardiol.* 2016, 23, 1715–1733. [CrossRef]

22. Spruit, M.A.; Singh, S.J.; Garvey, C.; ZuWallack, R.; Nici, L.; Rochester, C.; Hill, K.; Holland, A.E.; Lareau, S.C.; Warth, A.; Kolb, M.; Herth, F.J. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. *PLoS ONE* 2011, 6, e188. [CrossRef] [PubMed]

23. Hornikx, M.; Van Remoortel, H.; Lehouck, A.; Mathieu, C.; Maes, K.; Gayan-Ramirez, G.; Decramer, M.; Troosters, T.; Janssens, W. Vitamin D supplementation during rehabilitation in COPD: A secondary analysis of a randomized trial. *Respir. Res.* 2012, 13, 84. [CrossRef] [PubMed]

24. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *PLoS Med.* 2009, 6, e1000097. [CrossRef] [PubMed]
25. Man, W.D.; Chowdhury, F.; Taylor, R.S.; Evans, R.A.; Doherty, P.; Singh, S.J.; Booth, S.; Thomason, D.; Andrews, D.; Lee, C. Building consensus for provision of breathlessness rehabilitation for patients with chronic obstructive pulmonary disease and chronic heart failure. *Chronic Respir. Dis.* 2016, 13, 229–239. [CrossRef] [PubMed]

26. Rochester, C.L.; Vogiatzis, I.; Holland, A.E.; Lareau, S.C.; Marciniuk, D.D.; Puhan, M.A.; Spruit, M.A.; Masefield, S.; Casaburi, R.; Clini, E.M. An official American Thoracic Society/European Respiratory Society policy statement: Enhancing implementation, use, and delivery of pulmonary rehabilitation. *Am. J. Respir. Crit. Care Med.* 2015, 192, 1373–1386. [CrossRef]

27. Thomas, B.; Ciliska, D.; Dobbins, M.; Micucci, S. A process for systematically reviewing the literature: Providing the research evidence for public health nursing interventions. *World Views Evid. Based Nurs.* 2004, 1, 176–184. [CrossRef]

28. Landis, J.R.; Koch, G.G. The measurement of observer agreement for categorical data. *Biometrics* 1977, 33, 159–174. [CrossRef]

29. Morris, S.B.; DeShon, R.P. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. *Psychol. Methods* 2002, 7, 105. [CrossRef]

30. Cohen, J. *Statistical Power Analysis for the Behavioral Sciences*, 2nd ed.; Erlbaum Associates: Hillsdale, MI, USA, 1988.

31. Abd El-Kader, S.M.; Al-Jifi, O.H. Exercise alleviates depression related systemic inflammation in chronic obstructive pulmonary disease patients. *Afr. Health Sci.* 2016, 16, 1078–1088. [CrossRef]

32. Abd El-Kader, S.M.; Al-Jifi, O.H.; Al-Jifi, H.O. Aerobic exercise training modulates bone mineral status in patients with chronic obstructive pulmonary disease. *Eur. J. Gen. Med.* 2016, 13, 51–54. [CrossRef]

33. Almadana Pacheco, V.; Pavon Masa, M.; Gomez-Bastero Fernandez, A.P.; Muniz Rodriguez, A.M.; Tallon Moreno, R.; Montemayor Rubio, T. Patient Profile of Drop-Outs From a Pulmonary Rehabilitation Program. *Arch. De Bronconeumol.* 2017, 53, 257–262. [CrossRef] [PubMed]

34. Altenburg, W.A.; Duiverman, M.L.; Ten Hacken, N.H.; Kerstjens, H.A.; de Greef, M.H.; Wijkstra, P.J.; Wempe, J.B. Changes in the endurance shuttle walk test in COPD patients with chronic respiratory failure after pulmonary rehabilitation: The minimal important difference obtained with anchor- and distribution-based method. *Respir. Res.* 2015, 16, 27. [CrossRef] [PubMed]

35. Amin, S.; Abrazado, M.; Quinn, M.; Storer, T.W.; Tseng, C.H.; Cooper, C.B. A controlled study of community-based exercise training in patients with moderate COPD. *BMC Pulm. Med.* 2014, 14, 125. [CrossRef] [PubMed]

36. Arnardottir, R.H.; Boman, G.; Larsson, K.; Hedenstrom, H.; Emtner, M. Interval training compared with continuous training in patients with COPD. *Respir. Med.* 2007, 101, 1196–1204. [CrossRef] [PubMed]

37. Averna, T.; Brunelli, S.; Delussu, A.S.; Porcacchia, P.; Lucarelli, E.; Polidori, L.; Traballes, M. Effects of a moderately intensive, 12-week training program on participants over 60 years of age with chronic obstructive pulmonary disease. *Med. Dello Sport* 2009, 62, 299–313.

38. Barakat, S.; Michele, G.; George, P.; Nicole, V.; Guy, A. Outpatient pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. *Int. J. Chronic Obstr. Pulm. Dis.* 2008, 3, 155–162.

39. Bendstrup, K.E.; Jensen, J.I.; Holm, S.; Bentgsson, B. Out-patient rehabilitation improves activities of daily living, quality of life and exercise tolerance in chronic obstructive pulmonary disease. *Eur. Respir. J.* 1997, 10, 2801–2806. [CrossRef] [PubMed]

40. Bernard, S.; Whittom, F.; Leblanc, P.; Jobin, J.; Belleau, R.; Berube, C.; Carrier, G.; Maltais, F. Aerobic and strength training in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 1999, 159, 896–901. [CrossRef]

41. Berry, M.J.; Adair, N.E.; Sevensky, K.S.; Quinby, A.; Lever, H.M. Inspiratory muscle training and whole-body reconditioning in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 1996, 153, 1812–1816. [CrossRef]

42. Berry, M.J.; Rejeski, W.J.; Adair, N.E.; Zaccaro, D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. *Am. J. Respir. Crit. Care Med.* 1999, 160, 1248–1253. [CrossRef]

43. Berry, M.J.; Rejeski, W.J.; Adair, N.E.; Ettinger Jr, W.H.; Zaccaro, D.J.; Sevick, M.A. A randomized, controlled trial comparing long-term and short-term exercise in patients with chronic obstructive pulmonary disease. *J. Cardiopulm. Rehabil.* 2003, 23, 60–68. [CrossRef] [PubMed]
44. Berry, M.J.; Rejeski, W.J.; Miller, M.E.; Adair, N.E.; Lang, W.; Foy, C.G.; Katula, J.A. A lifestyle activity intervention in patients with chronic obstructive pulmonary disease. *Respir. Med.* 2010, 104, 829–839. [CrossRef] [PubMed]

45. Berry, M.J.; Shields, K.L.; Adair, N.E. Comparison of Effects of Endurance and Strength Training Programs in Patients with COPD. *COPD* 2018, 15, 192–199. [CrossRef] [PubMed]

46. Bingisser, R.M.; Joos, L.; Frühauf, B.; Caravatti, M.; Knoblauch, A.; Villiger, P.M. Pulmonary rehabilitation in outpatients with asthma or chronic obstructive lung disease. *Swiss Med Wkly.* 2001, 131, 407–411. [PubMed]

47. Bisca, G.W.; Proenca, M.; Salomao, A.; Hernandez, N.A.; Pitta, F. Minimal detectable change of the London chest activity of daily living scale in patients with COPD. *J. Cardiopulm. Rehabil. Prev.* 2014, 34, 213–216. [CrossRef]

48. Boeselt, T.; Nell, C.; Lutteken, L.; Kehr, K.; Koepke, J.; Apelt, S.; Veith, M.; Beutel, B.; Spielmanns, M.; Greulich, T.; et al. Benefits of High-Intensity Exercise Training to Patients with Chronic Obstructive Pulmonary Disease: A Controlled Study. *Respir. Int. Rev. Thorac. Dis.* 2017, 93, 301–310. [CrossRef] [PubMed]

49. Borghi-Silva, A.; Mendes, R.G.; Trimer, R.; Oliveira, C.R.; Fregonezi, G.A.; Resquetti, V.R.; Arena, R.; Sampaio-Jorge, L.M.; Costa, D. Potential effect of 6 versus 12-weeks of physical training on cardiac autonomic function and exercise capacity in chronic obstructive pulmonary disease. *Eur. J. Phys. Rehabil. Med.* 2015, 51, 211–221.

50. Burtin, C.; Langer, D.; van Remoortel, H.; Demeyer, H.; Gosselink, R.; Decramer, M.; Dobbels, F.; Janssens, W.; Troosters, T. Physical Activity Counselling during Pulmonary Rehabilitation in Patients with COPD: A Randomised Controlled Trial. *PLoS ONE* 2015, 10, e0144989. [CrossRef]

51. Burtin, C.; Saey, D.; Saglam, M.; Langer, D.; Gosselink, R.; Janssens, W.; Decramer, M.; Maltais, F.; Troosters, T. Effectiveness of exercise training in patients with COPD: The role of muscle fatigue. *Eur. Respir. J.* 2012, 40, 338–344. [CrossRef]

52. Cambach, W.; Chadwick-Straver, R.V.; Wagenaar, R.C.; van Keimpema, A.R.; Kemper, H.C. The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: A randomized controlled trial. *Eur. Respir. J.* 1997, 10, 104–113. [CrossRef]

53. Camillo, C.A.; Laburu, V.D.M.; Gonalves, N.S.; Cavalheri, V.; Tomasi, F.P.; Hernandez, N.A.; Ramos, D.; Marquez Vanderlei, L.C.; Cipulo Ramos, E.M.; Probst, V.S.; et al. Improvement of heart rate variability after exercise training and its predictors in COPD. *Respir. Med.* 2011, 105, 1054–1062. [CrossRef] [PubMed]

54. Campos, A.A.; Cabrera, R.O.; Arancibia, H.F. Respiratory rehabilitation in COPD patients: Experience in a rural primary health care center. *Rev. Chil. De Enferm. Respir.* 2015, 31, 77–85.

55. Charikiopoulou, M.; Nikolaidis, P.T.; Knechtle, B.; Rosemann, T.; Rapti, A.; Trakada, G. Subjective and Objective Outcomes in Patients With COPD After Pulmonary Rehabilitation—The Impact of Comorbidities. *Front. Physiol.* 2019, 10, 286. [CrossRef] [PubMed]

56. Chen, R.; Chen, R.; Chen, X.; Chen, L. Effects of Endurance and Strength Training Programs in Patients with COPD and the Effects of the Rural Primary Health Care Center. *Eur. Intern. Med. J.* 2014, 44, 791–800. [CrossRef] [PubMed]

57. Cheng, S.T.; Wu, Y.K.; Yang, M.C.; Huang, C.Y.; Huang, H.C.; Chu, W.H.; Lan, C.C. Pulmonary rehabilitation improves heart rate variability at peak exercise, exercise capacity and health-related quality of life in chronic obstructive pulmonary disease. *Heart Lung J. Crit. Care* 2014, 43, 249–255. [CrossRef] [PubMed]

58. Clark, C.J.; Cochrane, L.M.; Mackay, E.; Paton, B. Skeletal muscle strength and endurance in patients with mild COPD and the effects of weight training. *Eur. Respir. J.* 2000, 15, 92–97. [CrossRef] [PubMed]

59. Corhay, J.L.; Nguyen, D.; Duysinx, B.; Graas, C.; Pirmay, F.; Bury, T.; Louis, R. Should we exclude elderly patients with chronic obstructive pulmonary disease from a long-time ambulatory pulmonary rehabilitation programme? *J. Rehabil. Med.* 2012, 44, 466–472. [CrossRef] [PubMed]

60. Cortopassi, F.; Castro, A.A.; Porto, E.F.; Colucci, M.; Fonseca, G.; Torre-Bouscoulet, L.; Iamonti, V.; Jardim, J.R. Comprehensive exercise training improves ventilatory muscle function and reduces dyspnea perception in patients with COPD. *Monaldi Arch. Chest Dis. Arch. Monaldi Per Le Mal. Del Torace* 2009, 71, 106–112. [CrossRef]

61. Covey, M.K.; Collins, E.G.; Reynerton, S.I.; Dilling, D.F. Resistance training as a preconditioning strategy for enhancing aerobic exercise training outcomes in COPD. *Respir. Med.* 2014, 108, 1141–1152. [CrossRef]
62. Covey, M.K.; McAuley, E.; Kapella, M.C.; Collins, E.G.; Alex, C.G.; Berbaum, M.L.; Larson, J.L. Upper-Body Resistance Training and Self-Efficacy Enhancement in COPD. J. Pulm. Respir. Med. 2012, 1 (Suppl. 9). [CrossRef]

63. Cox, N.J.M.; Hendricks, J.C.; Binkhorst, R.A.; van Herwaarden, C.L.A. A pulmonary rehabilitation program for patients with asthma and mild chronic obstructive pulmonary diseases (COPD). Lung Int. J. Lungs Air. Breath 1993, 171, 235–244. [CrossRef]

64. Crimi, C.; Heffler, E.; Augellietti, T.; Campisi, R.; Noto, A.; Vancheri, C.; Crimi, N. Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients. Int. J. Chronic Obstr. Pulm. Dis. 2018, 13, 3131–3139. [CrossRef] [PubMed]

65. Cruz, J.; Brooks, D.; Marques, A. Impact of feedback on physical activity levels of individuals with chronic obstructive pulmonary disease during pulmonary rehabilitation: A feasibility study. Chron. Respir. Dis. 2014, 11, 191–198. [CrossRef] [PubMed]

66. Cruz, J.; Brooks, D.; Marques, A. Walk2Bactive: A randomised controlled trial of a physical activity-focused behavioural intervention beyond pulmonary rehabilitation in chronic obstructive pulmonary disease. Chron. Respir. Dis. 2016, 13, 57–66. [CrossRef] [PubMed]

67. Da Costa, C.C.; de Azeredo Lermen, C.; Colombo, C.; Canterle, D.B.; Machado, M.L.L.; Kessler, A.; Teixeira, P.J.Z. Effect of a Pulmonary Rehabilitation Program on the levels of anxiety and depression and on the quality of life of patients with chronic obstructive pulmonary disease. Rev. Port. Pneumol. 2014, 20, 299–304. [CrossRef] [PubMed]

68. Da Silva Cardoso, M.C.; Sayão, L.B.; Souza, R.M.P.; De Melo Marinho, P.E. Pulmonary rehabilitation and whole-body vibration in chronic obstructive pulmonary disease. Mot. Rev. De Educ. Fis. 2016, 22, 44–50. [CrossRef]

69. da Silva, G.P.; Nascimento, F.A.; Macedo, T.P.; Morano, M.T.; Mesquita, R.; Pereira, E.D. Religious coping and respiratory disease. Upsala J. Med. Sci. 2015, 120, 52–58. [CrossRef] [PubMed]

70. Dourado, V.S.; Tanni, S.E.; Antunes, L.C.O.; Paiva, S.A.R.; Campana, A.O.; Renno, A.C.M.; Godoy, I. Effect of three exercise programs on patients with chronic obstructive pulmonary disease. Braz. J. Med Biol. Res. 2009, 42, 263–271. [CrossRef] [PubMed]

71. Dourado, V.Z.; Antunes, L.C.O.; Tanni, S.E.; Godoy, I. Factors associated with the minimal clinically important difference for health-related quality of life after physical conditioning in patients with COPD. J. Bras. De Pneumol. 2009, 35, 846–853. [CrossRef] [PubMed]

72. Effing, T.; Zielhuis, G.; Kersjens, H.; van der Valk, P.; van der Palen, J. Community based physiotherapeutic exercise in COPD self-management: A randomised controlled trial. Respir. Med. 2011, 105, 418–426. [CrossRef] [PubMed]

73. Emtner, M.; Hallin, R.; Arnaudottir, R.H.; Janson, C. Effect of physical training on fat-free mass in patients with chronic obstructive pulmonary disease (COPD). Upsala J. Med. Sci. 2015, 120, 52–58. [CrossRef] [PubMed]

74. Endo, Y.; Dobashi, K.; Uga, D.; Kato, D.; Nakazawa, R.; Sakamoto, M.; Fueki, M.; Makino, S. Effect of 12-month rehabilitation with low loading program on chronic respiratory disease. J. Phys. Ther. Sci. 2016, 28, 1032–1035. [CrossRef] [PubMed]

75. Enea, C.; Schmitt, N.; Dugú, B.; Boisseau, N.; Le Creff, C.; Denjean, A. Oxidative stress in patients with chronic obstructive pulmonary disease after aerobic exercise training. Sci. Sports 2005, 20, 48–50. [CrossRef]
80. Engel, R.M.; Gonski, P.; Beath, K.; Vemulpad, S. Medium term effects of including manual therapy in a pulmonary rehabilitation program for chronic obstructive pulmonary disease (COPD): A randomized controlled pilot trial. *J. Man. Manip. Ther.* 2016, 24, 80–89. [CrossRef]

81. Etnier, J.L.; Berry, M. Fluid intelligence in an older COPD sample after short- or long-term exercise. *Med. Sci. Sports Exerc.* 2001, 33, 1620–1628. [CrossRef]

82. Felcar, J.M.; Probst, V.S.; de Carvalho, D.R.; Merli, M.F.; Mesquita, R.; Vidotto, L.S.; Ribeiro, L.R.G.; Pitta, F. Effects of exercise training in water and on land in patients with COPD: A randomised clinical trial. *Physiotherapy* 2018, 104, 408–416. [CrossRef]

83. Fernandes, J.R.; da Silva, C.; da Silva, A.G.; Pinto, R.M.D.; Duarte, A.J.D.; Carvalho, C.R.; Benard, G. Effect of an Exercise Program on Lymphocyte Proliferative Responses of COPD Patients. *Lung* 2018, 196, 271–276. [CrossRef] [PubMed]

84. Fischer, M.J.; Scharloo, M.; Abbink, J.; van ’t Hul, A.; van Ranst, D.; Rudolphus, A.; Weinman, J.; Rabe, K.F.; Kaptein, A.A. Concerns about exercise are related to walk test results in pulmonary rehabilitation for patients with COPD. *Int. J. Behav. Med.* 2012, 19, 39–47. [CrossRef] [PubMed]

85. Foy, C.G.; Rejeski, W.J.; Berry, M.J.; Zaccaro, D.; Woodard, C.M. Gender moderates the effects of exercise therapy on health-related quality of life among COPD patients. *Chest* 2001, 119, 70–76. [CrossRef]

86. Fuld, J.P.; Kilduff, L.P.; Neder, J.A.; Pitsiladis, Y.; Lean, M.E.J.; Ward, S.A.; Cotton, M.M. Creatine supplementation during pulmonary rehabilitation in chronic obstructive pulmonary disease. *Thorax* 2005, 60, 531–537. [CrossRef] [PubMed]

87. Fuller, L.M.; Button, B.; Tarrant, B.; Steward, R.; Bennett, L.; Snell, G.; Holland, A.E. Longer Versus Shorter Duration of Supervised Rehabilitation After Lung Transplantation: A Randomized Trial. *Arch. Phys. Med. Rehabil.* 2017, 98, 220–226. [CrossRef] [PubMed]

88. Gayle, R.C.; Spitler, D.L.; Karper, W.B.; Jaeger, R.M.; Rice, S.N. Psychological changes in exercising COPD patients. *Int. J. Rehabil. Res. Int. Z. Fur Rehabil. Rev. Int. De Rech. De Readapt.* 1988, 11, 335–342. [CrossRef]

89. Georgiadou, O.; Vogiatzis, I.; Stratakos, G.; Koutsoukou, A.; Golemati, S.; Aliverti, A.; Roussos, C.; Zakynthinos, S. Effects of rehabilitation on chest wall volume regulation during exercise in COPD patients. *Eur. Respir. J.* 2007, 29, 284–291. [CrossRef] [PubMed]

90. Georgiopouloou, V.V.; Dimopoulos, S.; Sakellariou, D.; Papazachou, O.; Gerovasili, V.; Tasoulis, A.; Agapitou, V.; Vogiatzis, I.; Roussos, C.; Nanas, S. Cardiopulmonary rehabilitation enhances heart rate recovery in patients with COPD. *Respir. Care* 2012, 57, 2095–2103. [CrossRef]

91. Godoy, R.F.; Teixeira, P.J.; Becker Junior, B.; Michelli, M.; Godoy, D.V. Long-term repercussions of a pulmonary rehabilitation program on the indices of anxiety, depression, quality of life and physical performance in patients with COPD. *J. Bras. De Pneumol. Publ. Da Soc. Bras. De Pneumol. E Tislogia* 2009, 35, 129–136.

92. Goldstein, R.S.; Gort, E.H.; Avendano, M.A.; Stubbings, D.; Guyatt, G.H. Randomised controlled trial of respiratory rehabilitation. *Lancet* 1994, 344, 1394–1397. [CrossRef]

93. Grossbois, J.M.; Lamblin, C.; Lemaire, B.; Chekrourd, H.; Demis, J.M.; Douay, B.; Fortin, F. Long-term benefits of exercise maintenance after outpatient rehabilitation program in patients with chronic obstructive pulmonary disease. *J. Cardiopulm. Rehabil.* 1999, 19, 216–225. [CrossRef] [PubMed]

94. Guell, R.; Casan, P.; Belda, J.; Sangenis, M.; Morante, F.; Guyatt, G.H.; Sanchis, J. Long-term effects of outpatient rehabilitation of COPD—A randomized trial. *Chest* 2000, 117, 976–983. [CrossRef] [PubMed]

95. Harrison, S.L.; Beauchamp, M.K.; Sibley, K.; Araujo, T.; Romanou, J.; Goldstein, R.S.; Brooks, D. Minimizing the evidence-practice gap—A prospective cohort study incorporating balance training into pulmonary rehabilitation for individuals with chronic obstructive pulmonary disease. *BMC Pulm. Med.* 2015, 15, 73. [CrossRef] [PubMed]

96. Hoogendoorn, M.; van Wetering, C.R.; Schols, A.M.; Rutten-van Molken, M.P. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? *Eur. Respir. J.* 2010, 35, 79–87. [CrossRef] [PubMed]

97. Houben-Wilke, S.; Janssen, D.J.A.; Franssen, F.M.E.; Vanlenteren, L.; Wouters, E.F.M.; Spruit, M.A. Contribution of individual COPD assessment test (CAT) items to CAT total score and effects of pulmonary rehabilitation on CAT scores. *Health Qual. Life Outcomes* 2018, 16, 205. [CrossRef] [PubMed]

98. Jacome, C.; Marques, A. Short- and Long-term Effects of Pulmonary Rehabilitation in Patients With Mild COPD: A COMPARISON WITH PATIENTS WITH MODERATE TO SEVERE COPD. *J. Cardiopulm. Rehabil. Prev.* 2016, 36, 445–453. [CrossRef]
99. Jácome, C.; Marques, A. Impact of pulmonary rehabilitation in subjects with mild COPD. *Respir. Care* 2014, *59*, 1577–1582. [CrossRef]

100. Kamal, M.A.W.; Nambi, S.G.; Mahmoud, M.Z. Impact of Resisted Exercise on Chronic Obstructive Pulmonary Disease (COPD) in Elderly Patients in Alkharej, Saudi Arabia. *Int. J. Med Res. Health Sci.* 2016, *5*, 187–195.

101. Kanao, K.; Shiraishi, M.; Higashimoto, Y.; Maeda, K.; Sugiyama, R.; Okajima, S.; Chiba, Y.; Yamagata, T.; Terada, K.; Fukuda, K.; et al. Factors associated with the effect of pulmonary rehabilitation on physical activity in patients with chronic obstructive pulmonary disease. *Geriatr. Gerontol. Int.* 2017, *17*, 17–23. [CrossRef]

102. Kavoura, P.; Kostikas, K.; Tselebis, A.; Bratis, D.; Kosmas, E.; Alchanatis, M.; Koulouris, N.G.; Bakakos, P.; Loukides, S. Changes in BODE Quartiles After Pulmonary Rehabilitation Do Not Predict 2-Year Survival in Patients With COPD. *J. Cardiopulm. Rehabil. Prev.* 2016, *36*, 62–67. [CrossRef]

103. Kongsgaard, M.; Backer, V.; Jorgensen, K.; Kjaer, M.; Beyer, N. Heavy resistance training increases muscle size, strength and physical function in elderly male COPD-patients—A pilot study. *Respir. Med.* 2004, *98*, 1000–1007. [CrossRef] [PubMed]

104. Lan, C.C.; Chu, W.H.; Yang, M.C.; Lee, C.H.; Wu, Y.K.; Wu, C.P. Benefits of pulmonary rehabilitation in patients with COPD and normal exercise capacity. *Respir. Care* 2013, *58*, 1482–1488. [CrossRef] [PubMed]

105. Lan, C.C.; Yang, M.C.; Huang, H.C.; Yang, M.C.; Lee, C.H.; Huang, C.Y.; Wu, Y.K. Pulmonary rehabilitation improves subjective sleep quality in COPD. *Respir. Care* 2014, *59*, 1569–1576. [CrossRef] [PubMed]

106. Lan, C.C.; Yang, M.C.; Huang, H.C.; Wu, C.W.; Su, W.L.; Tzeng, I.S.; Wu, Y.K. Serial changes in exercise capacity, quality of life and cardiopulmonary responses after pulmonary rehabilitation in patients with chronic obstructive pulmonary disease. *Heart Lung J. Crit. Care* 2018, *47*, 477–484. [CrossRef] [PubMed]

107. Lan, C.C.; Yang, M.C.; Lee, C.H.; Huang, C.Y.; Huang, C.Y.; Huang, K.L.; Wu, Y.K. Pulmonary rehabilitation improves exercise capacity and quality of life in underweight patients with chronic obstructive pulmonary disease. *Respirology* 2011, *16*, 276–283. [CrossRef] [PubMed]

108. Leite, M.R.; Ramos, E.M.; Kalva-Filho, C.A.; Freire, A.P.; de Alencar Silva, B.S.; Nicolino, J.; de Toledo-Arruda, A.C.; Papoti, M.; Vanderlei, L.C.; Ramos, D. Effects of 12 weeks of aerobic training on autonomic modulation, mucociliary clearance, and aerobic parameters in patients with COPD. *Int. J. Chronic Obstr. Pulm. Dis.* 2015, *10*, 2549–2557. [CrossRef] [PubMed]

109. López Varela, M.V.; Anido, T.; Larrosa, M. Functional status and survival in patients with chronic obstructive pulmonary disease following pulmonary rehabilitation. *Arch. De Bronconeumol.* 2006, *42*, 434–439. [CrossRef]

110. Lox, C.L.; Freehill, A.J. Impact of pulmonary rehabilitation on self-efficacy, quality of life, and exercise tolerance. *Rehabil. Psychol.* 1999, *44*, 208–221. [CrossRef]

111. Maa, S.H.; Gauthier, D.; Turner, M. Acupressure as an adjunct to a pulmonary rehabilitation program. *J. Cardiopulm. Rehabil.* 1997, *17*, 268–276. [CrossRef]

112. Magadle, R.; McConnell, A.K.; Beckerman, M.; Weiner, P. Inspiratory muscle training in pulmonary rehabilitation program in COPD patients. *Respir. Med.* 2007, *101*, 1500–1505. [CrossRef]

113. Maltais, F.; LeBlanc, P.; Jobin, J.; Berube, C.; Bruneau, J.; Carrier, L.; Breton, M.J.; Falardeau, G.; Belleau, R. Intensity of training and physiologic adaptation in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 1997, *155*, 555–561. [CrossRef] [PubMed]

114. Maltais, F.; LeBlanc, P.; Simard, C.; Jobin, J.; Berube, C.; Bruneau, J.; Carrier, L.; Belleau, R. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 1996, *154*, 442–447. [CrossRef] [PubMed]

115. Mandigout, S.; Antonini, M.T.; Lafarge, Q.; Lemaire, F.; Dalmay, E.; Bouteille, B. Effects of training rehabilitation on the physical capacity of patients suffering from chronic obstructive pulmonary disease. *Sci. Sports* 2007, *22*, 300–301. [CrossRef]

116. Marques, A.; Gabriel, R.; Jácome, C.; Cruz, J.; Brooks, D.; Figueiredo, D. Development of a family-based pulmonary rehabilitation programme: An exploratory study. *Disabil. Rehabil.* 2015, *37*, 1340–1346. [CrossRef] [PubMed]

117. Marques, A.; Jácome, C.; Cruz, J.; Gabriel, R.; Brooks, D.; Figueiredo, D. Family-based psychosocial support and education as part of pulmonary rehabilitation in COPD: A randomized controlled trial. *Chest* 2015, *147*, 662–672. [CrossRef] [PubMed]
118. Marques, A.; Jacome, C.; Cruz, J.; Gabriel, R.; Figueiredo, D. Effects of a pulmonary rehabilitation program with balance training on patients with COPD. *J. Cardiopulm. Rehabil. Prev.* 2015, 35, 154–158. [CrossRef] [PubMed]
119. Marquez-Martín, E.; Ruiz, E.O.; Ramos, P.C.; López-Campos, J.L.; Azcona, B.V.; Cortés, E.B. Randomized trial of non-invasive ventilation combined with exercise training in patients with chronic hypercapnic failure due to chronic obstructive pulmonary disease. *Respir. Med.* 2014, 108, 1741–1751. [CrossRef]
120. Marquis, K.; Maltais, F.; Lacasse, Y.; Lacourciere, Y.; Fortin, C.; Poirier, P. Effects of aerobic exercise training and irbesartan on blood pressure and heart rate variability in patients with chronic obstructive pulmonary disease. *Can. Respir. J.* 2008, 15, 355–360. [CrossRef]
121. Mekki, M.; Paillard, T.; Sahli, S.; Tabka, Z.; Trabelsi, Y. Effects of 6 Months of Balance Training During Pulmonary Rehabilitation in Patients With COPD. *J. Cardiopulm. Rehabil. Prev.* 2015, 35, 207–213. [CrossRef]
122. Milani, R.V.; Lavie, C.J. Disparate effects of out-patient cardiac and pulmonary rehabilitation programs on work efficiency and peak aerobic capacity in patients with coronary disease or severe obstructive pulmonary disease. *J. Cardiopulm. Rehabil.* 1998, 18, 17–22. [CrossRef]
123. Mkacher, W.; Mekki, M.; Tabka, Z.; Trabelsi, Y. Effect of 6 Months of Balance Training During Pulmonary Rehabilitation in Patients With COPD. *J. Cardiopulm. Rehabil. Prev.* 2015, 35, 207–213. [CrossRef]
124. Moezy, A.; Erfani, A.; Mazaherinezhad, A.; Mousavi, S.A.J. Downhill walking influence on physical condition and quality of life in patients with COPD: A randomized controlled trial. *Med. J. Islam. Repub. Iran* 2018, 32, 49. [CrossRef]
125. Neunhauserer, D.; Steidle-Kloc, E.; Weiss, G.; Kaiser, B.; Niederseer, D.; Hartl, S.; Tschoeltscher, M.; Egger, A.; Schonfelder, M.; Lamprecht, B.; et al. Supplemental Oxygen During High-Intensity Exercise Training in Nonhypoxemic Chronic Obstructive Pulmonary Disease. *Am. J. Med.* 2016, 129, 1185–1193. [CrossRef]
126. Ortega, F.; Toral, J.; Cejudo, P.; Villagomez, R.; Sanchez, H.; Castillo, J.; Montemayor, T. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* 2002, 166, 669–674. [CrossRef]
127. Osadnik, C.R.; Loockx, M.; Louvaris, Z.; Demeyer, H.; Langer, D.; Rodrigues, F.M.; Janssens, W.; Vogiatzis, I.; Troosters, T. The likelihood of improving physical activity after pulmonary rehabilitation is increased in patients with COPD who have better exercise tolerance. *Int. J. Chronic Obstr. Pulm. Dis.* 2018, 13, 3515–3527. [CrossRef]
128. Panton, L.B.; Golden, J.; Broeder, C.E.; Browder, K.D.; Cestaro-Seifer, D.J.; Seifer, F.D. The effects of resistance training on functional outcomes in patients with chronic obstructive pulmonary disease. *Eur. J. Appl. Physiol.* 2004, 91, 443–449. [CrossRef]
129. Papp, M.E.; Wändell, P.E.; Lindfors, P.; Nygren-Bonnier, M. Effects of yogic exercises on functional capacity, lung function and quality of life in participants with obstructive pulmonary disease: A randomized controlled study. *Eur. J. Phys. Rehabil. Med.* 2017, 53, 447–461.
130. Pereira, E.D.B.; Viana, C.S.; Taunay, T.C.E.; Sales, P.U.; Lima, J.W.O.; Holanda, M.A. Improvement of Cognitive Function After a Three-Month Pulmonary Rehabilitation Program for COPD Patients. *Lung* 2011, 189, 279–285. [CrossRef]
131. Pitta, F.; Troosters, T.; Probst, V.S.; Langer, D.; Decramer, M.; Gosselink, R. Are patients with COPD more active after pulmonary rehabilitation? *Crit. Care* 2008, 12, 273–280. [CrossRef]
132. Polkey, M.I.; Quin, Z.H.; Zhou, L.; Zhu, M.D.; Wu, Y.X.; Chen, Y.Y.; Ye, S.P.; He, Y.S.; Jiang, M.; He, B.T.; et al. Tai Chi and Pulmonary Rehabilitation Compared for Treatment-Naive Patients With COPD: A Randomized Controlled Trial. *Chest* 2018, 153, 1116–1124. [CrossRef]
133. Probst, V.S.; Kovelis, D.; Hernandes, N.A.; Camillo, C.A.; Cavalheri, V.; Pitta, F. Effects of 2 exercise training programs on physical activity in daily life in patients with COPD. *Respir. Care* 2011, 56, 1799–1807. [CrossRef]
134. Probst, V.S.; Troosters, T.; Pitta, F.; Decramer, M.; Gosselink, R. Cardiopulmonary stress during exercise training in patients with COPD. *Eur. Respir. J.* 2006, 27, 1110–1118. [CrossRef]
135. Radom-Aizik, S.; Kaminski, N.; Hayek, S.; Halkin, H.; Cooper, D.M.; Ben-Dov, I. Effects of exercise training on quadriceps muscle gene expression in chronic obstructive pulmonary disease. *J. Appl. Physiol.* 2007, 102, 1976–1984. [CrossRef]
136. Rejbi, I.B.; Trabelsi, Y.; Chouchene, A.; Ben Turkia, W.; Ben Saad, H.; Zbidi, A.; Kerken, A.; Tabka, Z. Changes in six-minute walking distance during pulmonary rehabilitation in patients with COPD and in healthy subjects. *Int. J. Chronic Obstr. Pulm. Dis.* 2010, 5, 209–215. [CrossRef]

137. Rinaldo, N.; Bacchi, E.; Coratella, G.; Vitali, F.; Milanese, C.; Rossi, A.; Schena, F.; Lanza, M. Effects of Combined Aerobic-Strength Training vs Fitness Education Program in COPD Patients. *Int. J. Sports Med.* 2017, 38, 1001–1008. [CrossRef]

138. Rizk, A.K.; Wardini, R.; Chan-Thim, E.; Bacon, S.L.; Lavoie, K.L.; Pepin, V. Acute responses to exercise training and relationship with exercise adherence in moderate chronic obstructive pulmonary disease. *Chron. Respir. Dis.* 2015, 12, 329–339. [CrossRef]

139. Roman, M.; Larraz, C.; Gomez, A.; Ripoll, J.; Mir, I.; Miranda, E.Z.; Macho, A.; Thomas, V.; Esteve, M. Efficacy of pulmonary rehabilitation in patients with moderate chronic obstructive pulmonary disease: A randomized controlled trial. *BMC Fam. Pract.* 2013, 14, 21. [CrossRef]

140. Santana, V.T.S.; Squassoni, S.D.; Neder, J.A.; Fiss, E. Influence of current smoking on adherence and responses to pulmonary rehabilitation in patients with COPD. *Braz. J. Phys. Ther.* 2010, 14, 16–23. [CrossRef]

141. Scherer, Y.K.; Schneider, L.E. The effect of a pulmonary rehabilitation program on self-efficacy, perception of dyspnea, and physical endurance. *Heart Lung J. Crit. Care* 1997, 26, 15–22. [CrossRef]

142. Scherer, Y.K.; Schneider, L.E.; Shimmel, S. The effects of education alone and in combination with pulmonary rehabilitation on self-efficacy in patients with COPD. *Rehabil. Nurs. Off. J. Assoc. Rehabil. Nurses* 1998, 23, 71–77. [CrossRef]

143. Sciriha, A.; Lungaro-Mifsud, S.; Bonello, A.; Agius, T.; Scerri, J.; Ellul, B.; Fenech, A.; Camilleri, L.; Montefort, S. Systemic inflammation in COPD is not influenced by pulmonary rehabilitation. *Eur. J. Physiother.* 2017, 19, 194–200. [CrossRef]

144. Sciriha, A.; Lungaro-Mifsud, S.; Scerri, J.; Biloca, D.; Fsadni, C.; Fsadni, P.; Gerada, E.; Gouder, C.; Camilleri, L.; Montefort, S. Pulmonary rehabilitation in chronic obstructive pulmonary disease: Outcomes in a 12 week programme. *Eur. J. Physiother.* 2015, 17, 215–223. [CrossRef]

145. Sciriha, A.; Lungaro-Mifsud, S.; Scerri, J.; Magro, R.; Camilleri, L.; Montefort, S. Health status of COPD patients undergoing pulmonary rehabilitation: A comparative responsiveness of the CAT and SGRQ. *Chron. Respir. Dis.* 2017, 14, 352–359. [CrossRef]

146. Silva, B.S.A.; Lira, F.S.; Rossi, F.E.; Ramos, D.; Uzeloto, J.S.; Freire, A.; de Lima, F.F.; Gobbo, L.A.; Ramos, E.M.C. Inflammatory and Metabolic Responses to Different Resistance Training on Chronic Obstructive Pulmonary Disease: A Randomized Control Trial. *Front. Physiol.* 2018, 9, 262. [CrossRef]

147. Silva, B.S.A.; Ramos, D.; Bertolini, G.N.; Freire, A.; Leite, M.R.; Camillo, C.A.; Gobbo, L.A.; Ramos, E.M.C. Resistance exercise training improves mucociliary clearance in subjects with COPD: A randomized clinical trial. *Pulmonology* 2019. [CrossRef]

148. Skumlien, S.; Aure Skogedal, E.; Skrede Ryg, M.; Bjortuft, O. Endurance or resistance training in primary care after in-patient rehabilitation for COPD? *Respir. Med.* 2008, 102, 422–429. [CrossRef]

149. Solanes, I.; Guell, R.; Casan, P.; Sotomayor, C.; Gonzalez, A.; Feixas, T.; Gonzalez, M.; Guyatt, G. Duration of pulmonary rehabilitation to achieve a plateau in quality of life and walk test in COPD. *Respir. Med.* 2009, 103, 722–728. [CrossRef]

150. Spencer, L.M.; Alison, J.A.; McKeough, Z.J. A Survey of Opinions and Attitudes Toward Exercise Following a 12-month Maintenance Exercise Program for People with COPD. *Cardiopulm. Phys. Ther. J.* 2013, 24, 30–35. [CrossRef]

151. Spielmanns, M.; Fuchs-Bergsma, C.; Winkler, A.; Fox, G.; Krüger, S.; Baum, K. Effects of oxygen supply during training on subjects with COPD who are normoxemic at rest and during exercise: A blinded randomized controlled trial. *Respir. Care* 2015, 60, 540–548. [CrossRef]

152. Spruit, M.A.; Gosselink, R.; Troosters, T.; De Paeppe, K.; Decramer, M. Resistance versus endurance training in patients with COPD and peripheral muscle weakness. *Eur. Respir. J.* 2002, 19, 1072–1078. [CrossRef]

153. Spruit, M.A.; Gosselink, R.; Troosters, T.; Kasran, A.; Van Vliet, M.; Decramer, M. Low-grade systemic inflammation and the response to exercise training in patients with advanced COPD. *Chest* 2005, 128, 3183–3190. [CrossRef]

154. Stav, D.; Raz, M.; Shipirer, I. Three years of pulmonary rehabilitation: Inhibit the decline in airflow obstruction, improves exercise endurance time, and body-mass index, in chronic obstructive pulmonary disease. *BMC Pulm. Med.* 2009, 9, 26. [CrossRef]
155. Steinsbekk, A.; Lomundal, B.K. Three-year follow-up after a two-year comprehensive pulmonary rehabilitation program. Chron. Respir. Dis. 2009, 6, 5–11. [CrossRef] 
156. Strijbos, J.H.; Postma, D.S.; van Altena, R.; Gimoeno, F.; Koeter, G.H. Feasibility and effects of a home-care rehabilitation program in patients with chronic obstructive pulmonary disease. J. Cardiopulm. Rehabil. 1996, 16, 386–393. [CrossRef] 
157. Strijbos, J.H.; Postma, D.S.; van Altena, R.; Gimoeno, F.; Koeter, G.H. A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD - A follow-up of 18 months. Chest 1996, 109, 366–372. [CrossRef] 
158. Theander, K.; Jakobsson, P.; Jorgensen, N.; Unosson, M. Effects of pulmonary rehabilitation on fatigue, functional status and health perceptions in patients with chronic obstructive pulmonary disease: A randomized controlled trial. Clin. Rehabil. 2009, 23, 125–136. [CrossRef] 
159. Theodorakopoulou, E.P.; Gennimata, S.A.; Harikiopoulou, M.; Kaltsakas, G.; Palamidas, A.; Koutsoukou, A.; Roussos, C.; Kosmas, E.N.; Bakakos, P.; Koulouris, N.G. Effect of pulmonary rehabilitation on tidal expiratory flow limitation at rest and during exercise in COPD patients. Respir. Physiol. Neurobiol. 2017, 238, 47–54. [CrossRef] 
160. Toledo, A.; Borghi-Silva, A.; Sampaio, L.M.; Ribeiro, K.P.; Baldissera, V.; Costa, D. The impact of noninvasive ventilation during the physical training in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). Clinics 2007, 62, 113–120. [CrossRef] 
161. Trappenburg, J.C.; Troosters, T.; Spruit, M.A.; Vandebrouck, N.; Decramer, M.; Gosselink, R. Psychosocial conditions do not affect short-term outcome of multidisciplinary rehabilitation in chronic obstructive pulmonary disease. Arch. Phys. Med. Rehabil. 2005, 86, 1788–1792. [CrossRef] 
162. Troosters, T.; Gosselink, R.; Decramer, M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: A randomized trial. Am. J. Med. 2000, 109, 207–212. [CrossRef] 
163. Troosters, T.; Gosselink, R.; Decramer, M. Exercise training in COPD: How to distinguish responders from nonresponders. J. Cardiopulm. Rehabil. 2001, 21, 10–17. [CrossRef] 
164. Tselebis, A.; Bratis, D.; Pachi, A.; Moussas, G.; Ilias, I.; Harikiopoulou, M.; Theodorakopoulou, E.; Dumitr, S.; Kosmas, E.; Vgontzas, A.; et al. A pulmonary rehabilitation program reduces levels of anxiety and depression in COPD patients. Multidiscip. Respir. Med. 2013, 8. [CrossRef] 
165. Van de Bool, C.; Rutten, E.P.A.; van Helvoort, A.; Franssen, F.M.E.; Wouters, E.F.M.; Schols, A. A randomized clinical trial investigating the efficacy of targeted nutrition as adjunct to exercise training in COPD. J. Cachexia Sarcopenia Muscle 2017, 8, 748–758. [CrossRef] 
166. Van Helvoort, H.A.; de Boer, R.C.; van de Broek, L.; Dekhuijzen, R.; Heijdra, Y.F. Exercises commonly used in rehabilitation of patients with chronic obstructive pulmonary disease: Cardiopulmonary responses and effect over time. Arch. Phys. Med. Rehabil. 2011, 92, 111–117. [CrossRef] 
167. Vasilopoulou, M.; Papaioannou, A.I.; Kaltsakas, G.; Louvaris, Z.; Chynkiamis, N.; Spetsioti, S.; Kortianou, E.; Genimata, S.A.; Palamidas, A.; Kostikas, K.; et al. Home-based maintenance telex-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits. Eur. Respir. J. 2017, 49. [CrossRef] 
168. Voduc, N.; Tessier, C.; Sabri, E.; Fergusson, D.; Lavallee, L.; Aaron, S.D. Effects of oxygen on exercise duration in chronic obstructive pulmonary disease patients before and after pulmonary rehabilitation. Can. Respir. J. 2010, 17, e14–e19. [CrossRef] 
169. Vogiatzis, I.; Nanas, S.; Roussos, C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur. Respir. J. 2002, 20, 12–19. [CrossRef] 
170. Vogiatzis, I.; Williamson, A.F.; Miles, J.; Taylor, I.K. Physiological response to moderate exercise workloads in a pulmonary rehabilitation program in patients with varying degrees of airflow obstruction. Chest 1999, 116, 1200–1207. [CrossRef] 
171. Vonbank, K.; Strasser, B.; Mondryzky, J.; Marzluft, B.A.; Richter, B.; Losch, S.; Nell, H.; Petkov, V.; Haber, P. Strength training increases maximum working capacity in patients with COPD - Randomized clinical trial comparing three training modalities. Respir. Med. 2012, 106, 557–563. [CrossRef] 
172. Wada, J.T.; Borges-Santos, E.; Porras, D.C.; Paisani, D.M.; Cukier, A.; Lunardi, A.C.; Carvalho, C.R. Effects of aerobic training combined with respiratory muscle stretching on the functional exercise capacity and thoracoabdominal kinematics in patients with COPD: A randomized and controlled trial. Int. J. Chronic Obstr. Pulm. Dis. 2016, 11, 2691–2700. [CrossRef]
173. Wadell, K.; Henriksson-Larsen, K.; Lundgren, R.; Sundelin, G. Group training in patients with COPD—Long-term effects after decreased training frequency. *Disabil. Rehabil.* 2005, **27**, 571–581. [CrossRef] [PubMed]

174. Wadell, K.; Sundelin, G.; Henriksson-Larsen, K.; Lundgren, R. High intensity physical group training in water—An effective training modality for patients with COPD. *Respir. Med.* 2004, **98**, 428–438. [CrossRef] [PubMed]

175. Weiner, P.; Azgad, Y.; Ganam, R. Inspiratory muscle training combined with general exercise reconditioning in patients with COPD. *Chest* 1992, **102**, 1351–1356. [CrossRef] [PubMed]

176. Wijkstra, P.J.; Van Altena, R.; Kraan, J.; Otten, V.; Postma, D.S.; Koeter, G.H. Quality of life in patients with chronic obstructive pulmonary disease improves after rehabilitation at home. *Eur. Respir. J.* 1994, **7**, 269–273. [CrossRef] [PubMed]

177. Wijkstra, P.J.; van der Mark, T.W.; Kraan, J.; van Altena, R.; Koeter, G.H.; Postma, D.S. Effects of home rehabilitation on physical performance in patients with chronic obstructive pulmonary disease (COPD). *Eur. Respir. J.* 1996, **9**, 104–110. [CrossRef] [PubMed]

178. Wright, P.R.; Heck, H.; Langenkamp, H. Effects of a resistance training on pulmonary function and performance measurements in patients with chronic obstructive pulmonary disease. *Eur. J. Sport Sci.* 2003, **3**, 1–10. [CrossRef]

179. Wu, W.; Liu, X.; Liu, J.; Li, P.; Wang, Z. Effectiveness of water-based Liuzijue exercise on respiratory muscle strength and peripheral skeletal muscle function in patients with COPD. *Int. J. Chronic Obstr. Pulm. Dis.* 2018, **13**, 1713–1726. [CrossRef]

180. Xu, J.; He, S.; Han, Y.; Pan, J.; Cao, L. Effects of modified pulmonary rehabilitation on patients with moderate to severe chronic obstructive pulmonary disease: A randomized controlled trial. *Int. J. Nurs. Sci.* 2017, **4**, 219–224. [CrossRef]

181. Zambom-Ferraresi, F.; Cebollero, P.; Gorostiaga, E.M.; Hernandez, M.; Hueto, J.; Cascente, J.; Rezusta, L.; Val, L.; Anton, M.M. Effects of Combined Resistance and Endurance Training Versus Resistance Training Alone on Strength, Exercise Capacity, and Quality of Life in Patients With COPD. *J. Cardiopulm. Rehabil. Prev.* 2015, **35**, 446–453. [CrossRef]

182. ZuWallack, R.; Hashim, A.; McCusker, C.; Normandien, E.; Benoît-Conners, M.L.; Lahiri, B. The trajectory of change over multiple outcome areas during comprehensive outpatient pulmonary rehabilitation. *Chron. Respir. Dis.* 2006, **3**, 11–18. [CrossRef]

183. Zwerink, M.; Effing, T.; Kerstjens, H.A.; van der Valk, P.; Brusse-Keizer, M.; Zielhuis, G.; van der Palen, J. Cost-Effectiveness of a Community-Based Exercise Programme in COPD Self-Management. *COPD* 2016, **13**, 214–223. [CrossRef] [PubMed]

184. Abd El-Kader, S.M.; Al-Jiffri, O.H.; Ashmawy, E.M.; Gao, R.A. Treadmill walking exercise modulates bone mineral status and inflammatory cytokines in obese asthmatic patients with long term intake of corticosteroids. *Afr. Health Sci.* 2016, **16**, 798–808. [CrossRef] [PubMed]

185. Arandelovic, M.; Stankovic, I.; Nikolic, M. Swimming and persons with mild persistant asthma. *Sci. World J.* 2007, **7**, 1182–1188. [CrossRef]

186. Boyd, A.; Yang, C.T.; Estell, K.; Ms, C.T.; Gerald, L.B.; Dransfield, M.; Bamman, M.; Bonner, J.; Atkinson, T.P.; Schwiebert, L.M. Feasibility of exercising adults with asthma: A randomized pilot study. *Allergy Asthma Clin. Immunol. Off. J. Can. Soc. Allergy Clin. Immunol.* 2012, **8**, 13. [CrossRef] [PubMed]

187. Cochrane, L.M.; Clark, C.J. Benefits and problems of a physical training programme for asthmatic patients. *Thorax* 1990, **45**, 345–351. [CrossRef]
190. Dogra, S.; Kuk, J.L.; Baker, J.; Jamnik, V. Exercise is associated with improved asthma control in adults. *Eur. Respir. J.* 2011, 37, 318–323. [CrossRef]

191. Franca-Pinto, A.; Mendes, F.A.; de Carvalho-Pinto, R.M.; Agondi, R.C.; Cukier, A.; Stelmach, R.; Saraiva-Romanholo, B.M.; Kalil, J.; Martins, M.A.; Giavina-Bianchi, P.; et al. Aerobic training decreases bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: A randomised controlled trial. *Thorax* 2015, 70, 732–739. [CrossRef]

192. Goncalves, R.C.; Nunes, M.P.T.; Cukier, A.; Stelmach, R.; Martins, M.A.; Carvalho, C.R.F. Effects of an aerobic physical training program on psychosocial characteristics, quality-of-life, symptoms and exhaled nitric oxide in individuals with moderate or severe persistent asthma. *Braz. J. Phys. Ther.* 2008, 12, 127–135.

193. Haas, F.; Pasierski, S.; Levine, N.; Bishop, M.; Axen, K.; Pineda, H.; Haas, A. Effect of aerobic training on forced expiratory airflow in exercising asthmatic humans. *J. Appl. Physiol.* 1987, 63, 1230–1235. [CrossRef] [PubMed]

194. Mendes, F.A.R.; Goncalves, R.C.; Nunes, M.P.T.; Saraiva-Romanholo, B.M.; Cukier, A.; Stelmach, R.; Jacob-Filho, W.; Martins, M.A.; Carvalho, C.R.F. Effects of Aerobic Training on Psychosocial Morbidity and Symptoms in Patients With Asthma A Randomized Clinical Trial. *Chest* 2010, 138, 331–337. [CrossRef] [PubMed]

195. Igarashi, A.; Iwanami, Y.; Sugino, K.; Gocho, K.; Homma, S.; Ebihara, S. Using 6-Min Walk Distance Expressed as a Percentage of Reference to Evaluate the Effect of Pulmonary Rehabilitation in Elderly Patients With Interstitial Lung Disease. *J. Cardiopulm. Rehabil. Prev.* 2018, 38, 342–347. [CrossRef]

196. Jackson, R.M. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. *Respir. Care* 2014, 59, 1872–1879. [CrossRef] [PubMed]

197. Igarashi, A.; Iwanami, Y.; Sugino, K.; Gocho, K.; Homma, S.; Ebihara, S. Using 6-Min Walk Distance Expressed as a Percentage of Reference to Evaluate the Effect of Pulmonary Rehabilitation in Elderly Patients With Interstitial Lung Disease. *J. Cardiopulm. Rehabil. Prev.* 2018, 38, 342–347. [CrossRef] [PubMed]

198. Marcellis, R.; Van der Veen, E.; Meesters, I.; Drent, M.; De Bie, R.; De Vries, G.; Lenssen, A. Does physical training reduce fatigue in sarcoidosis? *Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. Wasog* 2015, 32, 53–62.

199. Naz, I.; Ozalevi, S.; Ozkan, S.; Sahin, H. Efficacy of a Structured Exercise Program for Improving Functional Capacity and Quality of Life in Patients With Stage 3 and 4 Sarcoidosis: A RANDOMIZED CONTROLLED TRIAL. *J. Cardiopulm. Rehabil. Prev.* 2018, 38, 124–130. [CrossRef]

200. Naz, I.; Sahin, H.; Uçsular, E.D.; Yalniz, E. A comparison trial of eight weeks versus twelve weeks of exercise program in interstitial lung diseases. *Sarcoidosis Vasc. Diffus. Lung Dis.* 2018, 35, 299–307.

201. Perez-Bogerd, S.; Wuyts, W.; Barbier, V.; Demeyer, H.; Van Muylem, A.; Janssens, W.; Troosters, T. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: A randomized controlled trial. *Respir. Respir. Res.* 2018, 19, 182. [CrossRef]

202. Sciriha, A.; Lungaro-Mifsud, S.; Fsadni, P.; Scerri, J.; Montefort, S. Pulmonary Rehabilitation in patients with Interstitial Lung Disease: The effects of a 12-week programme. *Respir. Med.* 2019, 146, 49–56. [CrossRef] [PubMed]

203. Strookappe, B.; Elfferich, M.; Swigris, J.; Verschoof, A.; Veschakelen, J.; Knevel, T.; Drent, M. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: A pilot study. *Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG* 2015, 32, 43–52.
207. Vainshelboim, B.; Kramer, M.R.; Fox, B.D.; Izhakian, S.; Sagie, A.; Oliveira, J. Supervised exercise training improves exercise cardiovascular function in idiopathic pulmonary fibrosis. *Eur. J. Phys. Rehabil. Med.* **2017**, *53*, 209–218. [PubMed]

208. Vainshelboim, B.; Oliveira, J.; Fox, B.D.; Soreck, Y.; Fruchter, O.; Kramer, M.R. Long-term effects of a 12-week exercise training program on clinical outcomes in idiopathic pulmonary fibrosis. *Lung* **2015**, *193*, 345–354. [CrossRef] [PubMed]

209. Vainshelboim, B.; Oliveira, J.; Yehoshua, L.; Weiss, I.; Fox, B.D.; Fruchter, O.; Kramer, M.R. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. *Respir. Int. Rev. Thorac. Dis.* **2014**, *88*, 378–388. [CrossRef] [PubMed]

210. Cazzola, M.; Calzetta, L.; Bettoncelli, G.; Novelli, L.; Cricelli, C.; Rogliani, P. Asthma and comorbid medical illness. *Eur. Respir. J.* **2011**, *38*, 42–49. [CrossRef] [PubMed]

211. King, C.S.; Nathan, S.D. Idiopathic pulmonary fibrosis: Effects and optimal management of comorbidities. *Lancet Respir. Med.* **2017**, *5*, 72–84. [CrossRef]

212. Fabbri, L.M.; Boyd, C.; Boschetto, P.; Rabe, K.F.; Buist, A.S.; Yawn, B.; Le, N.; Milani, R.V. Exercise and the cardiovascular system: Clinical science and cardiovascular outcomes. *Circ. Res.* **2015**, *117*, 207–219. [CrossRef]

213. Schulz, K.F.; Altman, D.G.; Moher, D. CONSORT 2010 statement: Updated guidelines for reporting parallel randomised trials. *BMJ Med.* **2010**, *8*, 18. [CrossRef] [PubMed]

214. Hsu, C.-Y.; Hsieh, P.-L.; Hsiao, S.-F.; Chien, M.-Y. Effects of exercise training on autonomic function in chronic heart failure: Systematic review. *Biomed Res. Int.* **2015**, *8*, [CrossRef] [PubMed]

215. Cornelis, N.; Nassen, J.; Buys, R.; Fourneau, I.; Cornelissen, V. The Impact of Supervised Exercise Training on Traditional Cardiovascular Risk Factors in Patients With Intermittent Claudication: A Systematic Review and Meta-Analysis. *Eur. J. Vasc. Endovasc. Surg.* **2019**, *58*, 75–87. [CrossRef] [PubMed]

216. Kachur, S.; Chongthammakun, V.; Lavie, C.J.; De Schutter, A.; Arena, R.; Milani, R.V.; Franklin, B.A. Impact of cardiac rehabilitation and exercise training programs in coronary heart disease. *Prog. Cardiovasc. Dis.* **2017**, *60*, 103–114. [CrossRef] [PubMed]

217. Lavie, C.J.; Arena, R.; Swift, D.L.; Johannsen, N.M.; Sui, X.; Lee, D.-c.; Earnest, C.P.; Church, T.S.; O’Keefe, J.H.; Milani, R.V. Exercise and the cardiovascular system: Clinical science and cardiovascular outcomes. *Circ. Res.* **2015**, *117*, 207–219. [CrossRef]

218. Hansen, D.; Dendale, P.; Coninx, K.; Vanhees, L.; Piepoli, M.F.; Niebauer, J.; Cornelissen, V.; Pedretti, R.; Geurts, E.; Ruiz, G.R. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. *Eur. J. Prev. Cardiol.* **2017**, *24*, 1017–1031. [PubMed]

219. American Association of Cardiovascular Pulmonary Rehabilitation. *Guidelines for Pulmonary Rehabilitation Programs*; Human Kinetics: Stanningley, UK, 2011.

220. Troosters, T.; Van Remoortel, H. Pulmonary rehabilitation and cardiovascular disease. *Semin. Respir. Crit. Care Med.* **2009**, *30*, 675–683. [CrossRef]

221. Hansen, D.; Piepoli, M.F.; Doehner, W. The importance of rehabilitation in the secondary prevention of cardiovascular disease. *Eur. J. Prev. Cardiol.* **2019**, *26*, 273–276. [CrossRef]

222. American College of Sports Medicine. *ACSM’S Guidelines for Exercise Testing and Prescription*; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2013.

223. Piepoli, M.F.; Corra, U.; Benzer, W.; Bjarnason-Wehrens, B.; Dendale, P.; Gaita, D.; McGee, H.; Mendes, M.; Niebauer, J.; Zwissler, A.-D.O. Secondary prevention through cardiac rehabilitation: From knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. *Eur. J. Cardiovasc. Prev. Rehabil.* **2010**, *17*, 1–17. [CrossRef]

224. Wenger, N.K. Current status of cardiac rehabilitation. *J. Am. Coll. Cardiol.* **2008**, *51*, 1619–1631. [CrossRef]